https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free-en.html https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/01_ParallelCapabilities_EN_v1.png Four parallel capability rows show Valo for human data and drug discovery, OpenAI for AI tools and workflow support, AWS for cloud and AI infrastructure, and Anthropic for scientific reasoning and software engineering. Four independent arrows lead to the Novo R&D workflow. There are no arrows between suppliers. A bottom note identifies this as a capability schematic, not proven clinical outcomes. Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/02_ThreeValueLayers_EN_v1.png Three parallel panels show data and a scientist exploring targets and candidates; clinical documents, manufacturing and supply-chain operations; and protein structures, molecular models and software tools. A bottom statement says experiments and clinical validation are still required. Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/03_RolesAndPayments_EN_v1.png Three columns show OpenAI and Anthropic models and tools, AWS cloud and data services, and Valo drug discovery. The Valo column separates equity financing from collaboration payments. The bottom distinguishes potential value, cash received and recognized revenue. Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free-en/04_ValidationGates_EN_v1.png Six R&D stages follow a serpentine path from data and hypotheses through AI screening, experiments, preclinical work, clinical trials and regulation/payment. An early-stage decision-speed cue is separate from later locked evidence requirements for human data, safety, efficacy and payment. No clinical stage is bypassed. Novo Nordisk teams up with Anthropic to bring Claude's reasoning and coding into drug R&D https://drugnews.com.tw/articles/2026-09-25-novo-nordisk-anthropic-ai-rd-workflow-free.html https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free/01_%E5%B9%B3%E8%A1%8C%E8%83%BD%E5%8A%9B_ZH_v1.png 四個平行能力框分別標示Valo的人體資料與藥物探索、OpenAI的AI工具與工作流程支援、AWS的雲端與AI基礎設施，以及Anthropic的科學推理與軟體工程。四條獨立連線共同指向Novo研發工作流程，供應商彼此沒有串聯箭頭。底部註明能力支援示意不代表已證臨床成果。諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試 https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free/02_%E4%B8%89%E5%B1%A4%E5%83%B9%E5%80%BC_ZH_v1.png 三個並列區塊分別呈現資料與科學家探索靶點和候選物、臨床文件與製造及供應鏈作業，以及蛋白結構、分子模型和程式工具。底部明示仍需實驗與臨床驗證。諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試 https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free/03_%E8%A7%92%E8%89%B2%E8%88%87%E6%AC%BE%E9%A0%85_ZH_v2.png 三欄依序呈現OpenAI與Anthropic的模型及工具、AWS雲端和資料服務、Valo藥物發現。Valo欄分開列股權融資與合作款項，底部明示潛在金額不等於已收款，也不等於已認列收入。諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試 https://drugnews.com.tw/assets/articles/novo-nordisk-anthropic-ai-rd-workflow-free/04_%E7%A0%94%E7%99%BC%E9%A9%97%E8%AD%89%E9%97%9C%E5%8D%A1_ZH_v1.png 六個研發階段以蛇形箭頭相連，從資料與假設、AI篩選到實驗驗證，再到臨床前、臨床試驗及監管／支付。前段有決策加速提示，後段以鎖頭標示人體資料、安全性、療效與支付要求，沒有跳過臨床的捷徑。諾和諾德攜手Anthropic：讓Claude推理、寫程式，投入新藥研發測試 https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en.html https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/01_EN_branded.png Figure 1. The deals address cell-therapy manufacturing and biologic formulation, with different rights structures. Why Are Lilly and Novartis Betting on How Medicines Are Delivered? https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/02_EN_branded.png Figure 2. In vivo CAR-T remains investigational. Intermediate molecular steps after vector entry are omitted. Why Are Lilly and Novartis Betting on How Medicines Are Delivered? https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/03_EN_branded.png Figure 3. ALT-B4 temporarily breaks down subcutaneous hyaluronan to aid dispersion and absorption of a co-administered drug. Why Are Lilly and Novartis Betting on How Medicines Are Delivered? https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026-en/04_EN_branded.png Figure 4. Lilly's consideration comprises an upfront commitment and contingent milestones. Alteogen's individual amounts are undisclosed, with royalties additional. Why Are Lilly and Novartis Betting on How Medicines Are Delivered? https://drugnews.com.tw/articles/2026-09-24-delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026.html https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/01_ZH_branded.png 圖1｜兩筆交易分別改變細胞治療製程與生物藥劑型，所取得的權利也不同。禮來與諾華的大交易，為什麼都看上「怎麼給藥」？ https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/02_ZH_branded.png 圖2｜體內CAR-T仍在研究中；示意省略載體進入後的中間分子步驟。禮來與諾華的大交易，為什麼都看上「怎麼給藥」？ https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/03_ZH_branded.png 圖3｜ALT-B4暫時分解皮下透明質酸，協助共同給藥的藥物分散與吸收。禮來與諾華的大交易，為什麼都看上「怎麼給藥」？ https://drugnews.com.tw/assets/articles/delivery-platform-deals-lilly-kelonia-novartis-alteogen-2026/04_ZH_branded.png 圖4｜禮來對價分前期約定與或有里程碑；Alteogen各項金額未公開，權利金另計。禮來與諾華的大交易，為什麼都看上「怎麼給藥」？ https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception-en.html https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception-en/01_RiskWindow_en.png Figure 1 schematic: Lynch syndrome increases cancer risk; NOUS-209 aims to train immune recognition of shared frameshift peptides, but immune response is not proven cancer prevention. Can a Vaccine Intercept Cancer Before It Develops? Early Research in People With Lynch Syndrome https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception-en/02_ImmuneRecognition_en.png Figure 2 schematic: NOUS-209 uses a GAd prime and MVA boost to deliver 209 shared frameshift peptides and induce T-cell recognition of MSI-related abnormal cells; it is not mRNA and not gene repair. Can a Vaccine Intercept Cancer Before It Develops? Early Research in People With Lynch Syndrome https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception-en/03_Denominators_en.png Figure 3 schematic: 45 participants in safety analysis, 37 evaluable for week-9 immune response, and 43 completing end-of-study colonoscopy; immune response, colonoscopy observations and prevention efficacy are different evidence layers. Can a Vaccine Intercept Cancer Before It Develops? Early Research in People With Lynch Syndrome https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception-en/04_EvidenceRoadmap_en.png Figure 4 schematic: To determine whether NOUS-209 truly provides clinical cancer-prevention benefit, larger randomized controlled studies with longer follow-up are still needed; current data support safety and immunogenicity signals, not proven reduction in cancer incidence. Can a Vaccine Intercept Cancer Before It Develops? Early Research in People With Lynch Syndrome https://drugnews.com.tw/articles/2026-09-23-lynch-nous209-cancer-interception.html https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception/01_%E9%81%BA%E5%82%B3%E9%A2%A8%E9%9A%AA_zh.png 圖1示意：Lynch syndrome 帶來較高癌症風險；NOUS-209 目標是訓練免疫系統辨認共享 frameshift peptide，但免疫反應不等於已證防癌率。癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究 https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception/02_%E5%85%8D%E7%96%AB%E8%BE%A8%E8%AD%98_zh.png 圖2示意：NOUS-209 以 GAd 初針與 MVA 加強針遞送 209 個共享 frameshift peptide，目標是誘發 T 細胞辨認 MSI 相關異常細胞；這不是 mRNA，也不是基因修復。癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究 https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception/03_%E4%B8%89%E7%A8%AE%E5%88%86%E6%AF%8D_zh.png 圖3示意：45 人安全性分析、37 人第 9 週可評估免疫反應、43 人完成末次腸鏡；免疫反應、腸鏡觀察與防癌效力是不同層次。癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究 https://drugnews.com.tw/assets/articles/lynch-nous209-cancer-interception/04_%E8%AD%89%E6%93%9A%E8%B7%AF%E5%BE%91_zh.png 圖4示意：要判斷 NOUS-209 是否真的帶來臨床防癌效益，仍需要更大、隨機、有對照、追蹤更久的研究；目前資料支持安全性與免疫原性訊號，但不等於已證明降低癌症發生率。癌症還沒出現，疫苗能先攔截嗎？遺傳高風險族群的早期研究 https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence-en.html https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/01_BiomarkerAndOutcomes_en.png Lp(a) reduction is a biomarker change, while the primary cardiovascular endpoint is the clinical outcome; HORIZON lowered the marker but missed the primary endpoint, which should not be interpreted as an effect precisely equal to zero. After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt? https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/02_TrialDesign_en.png HORIZON enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a), randomized to pelacarsen or placebo; this is a trial design schematic, not a result distribution. After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt? https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/03_KnownAndUnknown_en.png What is known is the initial conclusion and the missed primary endpoint; effect size, uncertainty intervals, event components, and complete safety data still require formal presentation. After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt? https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence-en/04_NextDataset_en.png The next complete dataset should be read through four lenses: main effect estimate and uncertainty, absolute risk and event components, prespecified populations, and safety plus data completeness. After Novartis’ 8,323-Patient Trial Setback, How Should the Cardiovascular Business Case Be Rebuilt? https://drugnews.com.tw/articles/2026-09-22-pelacarsen-horizon-topline-evidence.html https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/01_%E6%8C%87%E6%A8%99%E8%88%87%E7%B5%90%E5%B1%80_zh.png Lp(a) 降低屬於生物標記變化，主要心血管終點才是臨床結局；HORIZON 指標下降但主要終點未達標，不能解讀為效果精確為零。諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？ https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/02_%E8%A9%A6%E9%A9%97%E8%A8%AD%E8%A8%88_zh.png HORIZON 設計為 8,323 名已有心血管疾病且 Lp(a) 升高病人，隨機接受 pelacarsen 或安慰劑；這是試驗設計示意，不是結果分布。諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？ https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/03_%E5%B7%B2%E7%9F%A5%E8%88%87%E6%9C%AA%E7%9F%A5_zh.png 目前已知的是初步結論與主要終點未達標；效果量、區間、事件分項與完整安全性仍待正式資料。諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？ https://drugnews.com.tw/assets/articles/pelacarsen-horizon-topline-evidence/04_%E4%B8%8B%E4%B8%80%E4%BB%BD%E6%95%B8%E6%93%9A_zh.png 下一份完整資料應看四件事：主要效果及不確定區間、絕對風險與事件組成、預先指定族群、安全性與資料完整度。諾華8,323人試驗受挫，心血管新藥的生意要怎麼重算？ https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda-en.html https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda-en/01_en_ThreeEvidenceLevels_20260918.png ET is approved; two-year extension data and a separate 55-patient retrospective cohort should be read separately; PMF DSMB continuation is not efficacy success or approval. PharmaEssentia After a New Indication Approval: A US$46 Million Plant Plan for Long-Term Supply https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda-en/02_en_Mechanisms_20260918_v2.png MIMRYLO limits available iron via ferroportin/hepcidin biology, while BESREMi works through interferon signaling; there is no head-to-head trial. PharmaEssentia After a New Indication Approval: A US$46 Million Plant Plan for Long-Term Supply https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda-en/03_en_PMF_StudyMilestones_20260918.png The specific PMF study continues; follow-up, analysis and regulatory review still require formal evidence. This is not approval. PharmaEssentia After a New Indication Approval: A US$46 Million Plant Plan for Long-Term Supply https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda-en/04_en_EvidenceToRevenue_20260918_v2.png After approval, physician selection, reimbursement and treatment persistence still matter; availability is not the same as reimbursement or recurring revenue. PharmaEssentia After a New Indication Approval: A US$46 Million Plant Plan for Long-Term Supply https://drugnews.com.tw/articles/2026-09-21-pharmaessentia-besremi-et-mimrylo-fda.html https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda/01_%E4%B9%9D%E6%9C%88%E6%96%B0%E8%A8%8A_%E4%B8%89%E5%B1%A4%E8%AD%89%E6%93%9A_%E8%B1%90%E5%AF%8C%E7%89%88_20260918.png ET 已核准；兩年延伸研究與另一項 55 人回溯性隊列分開；PMF DSMB 建議繼續不代表療效成功或核准。藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda/02_%E6%A9%9F%E8%BD%89%E8%88%87%E8%AD%89%E6%93%9A%E9%82%8A%E7%95%8C_20260918_v2.png MIMRYLO 經鐵輸出蛋白限制可用鐵，BESREMi 經干擾素訊號調節異常造血；沒有頭對頭試驗。藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda/03_PMF_%E7%A0%94%E7%A9%B6%E9%97%9C%E5%8D%A1_20260918_v2.png 特定 PMF 族群研究續行；追蹤、分析與監管仍需正式證據，不是已核准。藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-et-mimrylo-fda/04_%E8%AD%89%E6%93%9A%E5%88%B0%E6%94%B6%E5%85%A5_20260918_v2.png 核准之後仍需醫師選人、支付與持續治療；可供應不等於已給付或持續收入。藥華藥新適應症獲准，4,600萬美元設廠計畫布局長期供應 https://drugnews.com.tw/articles/2026-09-18-ma-beta-asset-alpha-biopharma-deals.html https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/01_MA_beta%E4%B8%8B%E9%99%8D%E8%88%87asset_alpha%E4%B8%8A%E5%8D%87_typed_v1.png 圖 1｜M&A beta 降，asset alpha 為何可能升大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升 https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/02_%E8%B2%B7%E6%96%B9%E5%89%B5%E6%96%B0%E8%B3%87%E7%94%A2%E8%A3%9C%E5%BA%AB%E7%8B%80%E6%85%8B%E5%88%86%E5%B2%94_typed_v1.png 圖 2｜買方創新資產補庫狀態分岔大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升 https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/03_%E8%B3%87%E7%94%A2%E5%8F%AF%E9%A9%97%E8%AD%89%E6%80%A7%E5%9B%9B%E9%81%93%E9%96%98%E9%96%80_typed_v1.png 圖 3｜資產可驗證性四道閘門大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升 https://drugnews.com.tw/assets/articles/ma-beta-asset-alpha-biopharma-deals/04_%E4%B8%AD%E5%9C%8Bbiotech%E6%AC%8A%E5%88%A9%E8%88%87%E4%BA%A4%E6%98%93%E9%82%8A%E7%95%8C_typed_v1.png 圖 4｜中國 biotech 的權利與交易邊界大藥廠不是沒錢，是交易條件變窄了：M&A beta 降溫後，asset alpha 為何可能上升 https://drugnews.com.tw/articles/2026-09-17-mfn26-beone-policy-bargain.html https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/01_MFN%E4%BA%8C%E5%8D%81%E5%85%AD%E5%AE%B6%E8%88%87%E5%85%AB%E5%8D%81%E4%B9%9D%E7%99%BE%E5%88%86%E6%AF%94%E6%94%BF%E7%AD%96%E8%A6%86%E8%93%8B%E5%8F%8D%E5%B7%AE_typed_v1.png 圖 1｜26 家與 89% 是政策廣度，不是條款成熟度 26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？ https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/02_GENEROUS%E5%B7%9E%E8%A3%9C%E5%85%85%E8%BF%94%E5%88%A9%E8%88%87%E8%87%AA%E9%A1%98%E5%8F%83%E8%88%87%E6%A9%9F%E5%88%B6_typed_v1.png 圖 2｜GENEROUS 從 CMS 框架走到州補充返利 26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？ https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/03_%E7%99%BD%E5%AE%AEBeOne%E8%88%87Teva%E5%8D%94%E8%AD%B0%E6%88%90%E7%86%9F%E5%BA%A6%E5%B7%AE%E7%95%B0_typed_v1.png 圖 3｜白宮、BeOne、Teva 的協議成熟度不可混寫 26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？ https://drugnews.com.tw/assets/articles/mfn26-beone-policy-bargain/04_%E8%97%A5%E5%83%B9%E6%8A%95%E8%B3%87%E8%88%87API%E4%BE%9B%E6%87%89%E9%8F%88%E4%BA%A4%E6%8F%9B%E5%B8%B3_typed_v1.png 圖 4｜藥價、投資與 API 供應鏈是同一張交換帳 26 家藥廠、89% 市場覆蓋：MFN 藥價協議真正落地到哪一層？ https://drugnews.com.tw/articles/2026-09-14-cd47-after-pipeline-exits.html https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/01_%E5%B0%81%E9%9D%A2_CD47%E4%B8%8D%E6%98%AF%E5%9C%98%E6%BB%85%E6%98%AF%E8%B7%AF%E7%B7%9A%E6%B7%98%E6%B1%B0.png 圖 1｜Pfizer 停止 maplirpacept 開發後，CD47 剩餘四種可投資路線 Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？ https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/02_%E9%80%80%E5%87%BA%E8%A1%A8_%E4%B8%89%E7%A8%AE%E5%A4%B1%E6%95%97%E4%B8%8D%E8%83%BD%E6%B7%B7%E6%88%90%E4%B8%80%E7%A8%AE.png 圖 2｜Magrolimab、maplirpacept、evorpacept 的退出理由不能混寫 Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？ https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/03_%E5%89%A9%E9%A4%98%E5%9B%9B%E7%89%8C_%E7%B5%84%E5%90%88%E5%88%86%E5%B1%A4%E6%B8%9B%E6%AF%92%E4%BA%BA%E9%AB%94%E8%AD%89%E6%93%9A.png 圖 3｜CD47 剩餘四張牌：組合、分層、減毒、人體證據 Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？ https://drugnews.com.tw/assets/articles/cd47-after-pipeline-exits/04_%E6%8A%95%E8%B3%87%E6%AA%A2%E6%9F%A5%E8%A1%A8_%E5%85%88%E7%9C%8B%E5%88%86%E6%AF%8D%E5%86%8D%E7%9C%8BORR.png 圖 4｜CD47 投資檢查表：先看分母、終點與證據層級 Pfizer 22.6 億美元收購 Trillium 後，maplirpacept 停止開發，CD47 還剩哪四條路？ https://drugnews.com.tw/articles/2026-09-13-eplontersen-attr-cm-incremental-value.html https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/01_%E4%B8%80%E5%8D%83%E5%9B%9B%E7%99%BE%E4%B8%89%E5%8D%81%E4%BA%8C%E4%BA%BA%E4%B8%89%E6%9C%9F%E6%9C%AA%E9%81%94%E6%A8%99_typed_v1.png 圖 1｜1,432 人三期未達標 1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？ https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/02_TTR%E5%85%A9%E5%80%8B%E4%BB%8B%E5%85%A5%E9%BB%9E_typed_v1.png 圖 2｜ATTR 的兩個介入點不保證結果相加 1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？ https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/03_%E8%83%8C%E6%99%AF%E6%B2%BB%E7%99%82%E6%99%82%E9%96%93%E5%88%86%E5%B1%A4_typed_v1.png 圖 3｜57% baseline 與另 24% on-study 不是同一時間點 1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？ https://drugnews.com.tw/assets/articles/eplontersen-attr-cm-incremental-value/04_%E5%A2%9E%E9%87%8F%E5%83%B9%E5%80%BC%E8%88%87%E5%8F%B0%E7%81%A3%E4%BA%9E%E6%B4%B2%E6%B1%BA%E7%AD%96_typed_v1.png 圖 4｜下一題是誰先用、誰加藥、值不值得付 1,432 人三期未達標：Eplontersen 加上標準治療後還剩多少價值？ https://drugnews.com.tw/articles/2026-09-12-autoimmune-car-t-safety-market-reset.html https://drugnews.com.tw/assets/articles/autoimmune-car-t-safety-market-reset/01_%E5%85%8D%E7%96%AB%E9%87%8D%E7%BD%AE%E8%88%87%E5%B0%BE%E7%AB%AF%E9%A2%A8%E9%9A%AA_typed_v1.png 圖 1｜免疫重置也要算尾端風險自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？ https://drugnews.com.tw/assets/articles/autoimmune-car-t-safety-market-reset/02_%E8%87%AA%E5%85%8DCAR-T%E5%AE%8C%E6%95%B4%E7%85%A7%E8%AD%B7%E8%B7%AF%E5%BE%91_typed_v1.png 圖 2｜自免 CAR-T 是一整條照護路徑自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？ https://drugnews.com.tw/assets/articles/autoimmune-car-t-safety-market-reset/03_%E5%85%AB%E5%8D%81%E4%B8%89%E4%BA%BA%E7%99%82%E6%95%88%E9%A2%A8%E9%9A%AA%E5%90%8C%E5%B8%B3_typed_v1.png 圖 3｜83 人早期資料把療效與風險放在同一帳自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？ https://drugnews.com.tw/assets/articles/autoimmune-car-t-safety-market-reset/04_%E6%B2%BB%E7%99%82%E4%B8%AD%E5%BF%83%E8%88%87%E5%8F%B0%E7%81%A3%E4%BA%9E%E6%B4%B2%E6%B1%BA%E7%AD%96_typed_v1.png 圖 4｜真正產品是治療中心能否安全承接自免 CAR-T 第一次被迫重算：療效之外，尾端安全風險如何縮小市場？ https://drugnews.com.tw/articles/2026-09-11-google-coscientist-real-world-lab-loop.html https://drugnews.com.tw/assets/articles/google-coscientist-real-world-lab-loop/01_AI%E6%8E%A5%E4%B8%8A%E5%AF%A6%E9%A9%97%E5%8F%B0_typed_v1.png 圖 1｜AI 已接上實驗台，但人仍在責任鏈 AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關 https://drugnews.com.tw/assets/articles/google-coscientist-real-world-lab-loop/02_%E7%A0%94%E7%A9%B6%E9%96%89%E7%92%B0_typed_v1.png 圖 2｜研究閉環：構思、執行、驗證與可追溯紀錄 AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關 https://drugnews.com.tw/assets/articles/google-coscientist-real-world-lab-loop/03_%E8%87%AA%E4%B8%BB%E7%A8%8B%E5%BA%A6_typed_v1.png 圖 3｜自主程度不同；濕實驗仍是 human-in-the-loop AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關 https://drugnews.com.tw/assets/articles/google-coscientist-real-world-lab-loop/04_%E6%8E%A1%E8%B3%BC%E6%B1%BA%E7%AD%96_typed_v1.png 圖 4｜可驗證導入場景：重現、稽核與責任 AI 一小時做完實驗？Google Co-Scientist 真正跨過的，是「動手」這一關 https://drugnews.com.tw/articles/2026-09-10-openai-rosalind-workbench.html https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/01_%E5%B0%81%E9%9D%A2_Codex%E8%AE%8A%E8%BA%ABAI%E7%A7%91%E5%AD%B8%E5%AE%B6.png 圖 1｜cover Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流 https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/02_Rosalind%E4%B8%89%E5%B1%A4%E6%9E%B6%E6%A7%8B.png 圖 2｜body-2 Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流 https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/03_%E7%A0%94%E7%A9%B6%E9%96%89%E7%92%B0.png 圖 3｜body-3 Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流 https://drugnews.com.tw/assets/articles/openai-rosalind-workbench/04_%E5%95%86%E6%A5%AD%E5%8C%96%E5%9B%9B%E9%97%9C.png 圖 4｜body-4 Codex 變身 AI 科學家？OpenAI 真正搶的是整套生命科學工作流 https://drugnews.com.tw/articles/2026-09-09-personalized-mrna-cancer-vaccine-economics.html https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/01_%E5%B0%81%E9%9D%A2_%E4%B8%80%E4%BA%BA%E4%B8%80%E6%94%AF%E7%99%8C%E7%97%87%E7%96%AB%E8%8B%97.png 圖 1｜cover 「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳 https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/02_%E5%80%8B%E4%BA%BA%E5%8C%96%E7%99%8C%E7%97%87%E7%96%AB%E8%8B%97_%E5%BE%9E%E8%85%AB%E7%98%A4%E5%88%B0%E5%B0%88%E5%B1%AC%E8%97%A5%E7%89%A9.png 圖 2｜body-2 「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳 https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/03_INTerpath001%E4%B8%89%E6%9C%9F_%E9%81%94%E6%A8%99%E8%88%87%E6%9C%AA%E5%85%AC%E5%B8%83%E9%82%8A%E7%95%8C.png 圖 3｜body-3 「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳 https://drugnews.com.tw/assets/articles/personalized-mrna-cancer-vaccine-economics/04_%E5%80%8B%E4%BA%BA%E5%8C%96mRNA%E5%95%86%E6%A5%AD%E5%8C%96_%E5%9B%9B%E5%A5%97%E7%B3%BB%E7%B5%B1%E8%88%87%E5%8F%B0%E7%81%A3%E4%B8%AD%E5%BF%83.png 圖 4｜body-4 「一針近 50 萬美元」有證據嗎？Moderna 三期後真正要算的四筆帳 https://drugnews.com.tw/articles/2026-09-08-big-pharma-bbb-delivery.html https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/01_%E5%B0%81%E9%9D%A2_BigPharma%E9%9B%86%E9%AB%94%E9%A4%8A%E9%A6%AC.png 圖 1｜Big Pharma 集體養馬：BBB delivery 成為 CNS 管線入口 Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口 https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/02_BBB%E6%9C%A8%E9%A6%AC%E8%B7%A8%E8%86%9C%E6%A9%9F%E5%88%B6.png 圖 2｜受體介導跨胞運輸：木馬如何把不同 cargo 送過 BBB Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口 https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/03_BBB%E4%BA%A4%E6%98%93%E8%88%87%E7%AD%96%E7%95%A5%E5%9C%B0%E5%9C%96.png 圖 3｜六家大藥廠的 BBB delivery 交易地圖 Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口 https://drugnews.com.tw/assets/articles/big-pharma-bbb-delivery/04_BBB%E4%BC%B0%E5%80%BC%E9%97%9C%E5%8D%A1%E8%88%87%E5%8F%B0%E7%81%A3%E8%A7%80%E5%AF%9F.png 圖 4｜BBB delivery 的估值階梯、五道關卡與台灣觀察點 Big Pharma 集體變養馬人！血腦屏障成了 CNS 新藥最貴入口 https://drugnews.com.tw/articles/2026-09-07-fda-ai-review-institutionalization.html https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/01_%E5%B0%81%E9%9D%A2_FDA%E5%B0%9A%E6%9C%AA%E5%AE%98%E5%AE%A3AI%E5%89%AF%E5%B1%80%E9%95%B7.png 圖 1｜FDA AI 副局長尚未官宣，AI 審評制度已經先行 FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值 https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/02_FDA%E4%B8%89%E6%A2%9DAI%E8%BB%8C%E9%81%93.png 圖 2｜FDA 的三條 AI 軌道：內部工具、申報證據、AI 醫材 FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值 https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/03_AI%E7%94%B3%E5%A0%B1%E4%B8%83%E9%81%93%E5%8F%AF%E4%BF%A1%E5%BA%A6%E9%97%9C%E5%8D%A1.png 圖 3｜AI 模型進入藥物申報前的七道可信度關卡 FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值 https://drugnews.com.tw/assets/articles/fda-ai-review-institutionalization/04_AI%E8%97%A5%E4%BC%81%E4%BC%B0%E5%80%BC%E8%AD%89%E6%93%9A%E9%8F%88.png 圖 4｜投資人應看的不是 AI 標籤，而是可監管的證據鏈 FDA 還沒任命 AI 副局長，AI 審評已先改寫新藥估值 https://drugnews.com.tw/articles/2026-09-06-oral-macrocyclic-peptide-platform.html https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/01_%E5%B0%81%E9%9D%A2_%E6%8A%8A%E6%8A%97%E9%AB%94%E7%B4%9A%E7%B5%90%E5%90%88%E5%8A%9B%E5%A1%9E%E9%80%B2%E8%97%A5%E7%89%87.png 圖 1｜cover 把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽 https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/02_%E4%B8%89%E7%A8%AE%E5%88%86%E5%AD%90%E7%9A%84%E6%88%90%E8%97%A5%E7%A9%BA%E9%96%93.png 圖 2｜body-2 把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽 https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/03_%E5%8F%A3%E6%9C%8D%E5%A4%A7%E7%92%B0%E8%82%BD%E7%94%A2%E6%A5%AD%E9%80%B2%E5%BA%A6%E5%9C%B0%E5%9C%96.png 圖 3｜body-3 把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽 https://drugnews.com.tw/assets/articles/oral-macrocyclic-peptide-platform/04_%E5%B9%B3%E5%8F%B0%E5%83%B9%E5%80%BC%E5%9B%9B%E9%81%93%E9%97%9C%E5%8D%A1.png 圖 4｜body-4 把抗體級結合力塞進藥片！兩款新藥獲批，大藥廠搶押口服大環肽 https://drugnews.com.tw/articles/2026-09-05-elecsys-ptau217-alzheimers-blood-test.html https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/01_%E5%B0%81%E9%9D%A2_18%E5%88%86%E9%90%98%E9%A9%97%E8%A1%80%E4%B8%8D%E6%98%AF%E7%A2%BA%E8%A8%BA.png 圖 1｜cover 18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」 https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/02_pTau217%E7%97%85%E7%90%86%E9%80%A3%E5%8B%95%E6%A9%9F%E5%88%B6.png 圖 2｜body-2 18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」 https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/03_%E8%AA%8D%E7%9F%A5%E4%B8%8B%E9%99%8D%E6%82%A3%E8%80%85%E5%88%86%E6%B5%81%E8%B7%AF%E5%BE%91.png 圖 3｜body-3 18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」 https://drugnews.com.tw/assets/articles/elecsys-ptau217-alzheimers-blood-test/04_%E6%82%A3%E8%80%85%E5%85%A5%E5%8F%A3%E8%88%87%E5%95%86%E6%A5%AD%E9%8F%88.png 圖 4｜body-4 18分鐘驗血，就能揪出阿茲海默症？禮來、羅氏真正搶的是「患者入口」 https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/cover.png Figure 1 | A PD-1 and VEGF bispecific platform moves from lung cancer into biliary tract cancer Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-02.png Figure 2 | HARMONi-GI1 cleared OS, PFS and ORR at the interim analysis, while five critical data gaps remain Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-03.png Figure 3 | Ivonescimab combines PD-1 immune release and VEGF pathway control in one tetravalent bispecific antibody Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-04.png Figure 4 | Five gates separate a positive China-only topline result from durable global clinical and commercial value Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/cover.png PD-1 與 VEGF 雙特異性抗體連結肺癌與肝膽研究場景的科學意象 Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷 https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-01.png Facebook 原圖 1｜Ivonescimab 從肺癌跨向膽道癌 Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷 https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-02.png Facebook 原圖 2｜HARMONi-GI1 三期已知結果與待公布數據 Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷 https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-03.png Facebook 原圖 3｜PD-1 與 VEGF 四價雙特異性抗體機制 Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷 https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1/facebook-04.png Facebook 原圖 4｜從中國三期陽性到全球商業價值的驗證路徑 Ivonescimab 跨出肺癌！正面挑戰膽道癌金標準，總生存期告捷 https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard-en.html https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard-en/cover.png Figure 1: Claude begins running experiments, moving AI from the screen to the bench Claude Starts Running Experiments: AI Enters the Physical Lab https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard-en/figure-02.png Figure 2: The MHS layer connects researchers and AI agents with instruments from different vendors Claude Starts Running Experiments: AI Enters the Physical Lab https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard-en/figure-03.png Figure 3: Proofs of concept in protein assays and high-throughput plate handling Claude Starts Running Experiments: AI Enters the Physical Lab https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard-en/figure-04.png Figure 4: The AI-lab value chain, beneficiaries and four risk gates Claude Starts Running Experiments: AI Enters the Physical Lab https://drugnews.com.tw/articles/2026-09-03-anthropic-mhs-ai-lab-hardware-standard.html https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard/cover.png 圖 1｜Claude 開始動手做實驗：AI 從螢幕走向實驗台 Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了 https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard/figure-02.png 圖 2｜MHS 共通層：研究者、AI 代理與多品牌設備如何連起來 Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了 https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard/figure-03.png 圖 3｜兩個實驗室案例：蛋白質測定與高通量設備交接 Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了 https://drugnews.com.tw/assets/articles/anthropic-mhs-ai-lab-hardware-standard/figure-04.png 圖 4｜AI 實驗室價值鏈：受益者、壓力與四道風險閘門 Claude 開始動手做實驗！AI 搶進真實實驗室，遊戲規則變了 https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley-en.html https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/cover.png Figure 1: A drug launch starts four clocks at once—revenue, cost, pipeline and capital A New Drug Launched. Seven Months Later, the Company Sought Liquidation https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-02.png Figure 2: Iterum's seven-month commercialization countdown—$0.4 million in revenue versus $6.5 million in expense A New Drug Launched. Seven Months Later, the Company Sought Liquidation https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-03.png Figure 3: Karyopharm's stress test—product revenue, cash, debt and new indications counting down together A New Drug Launched. Seven Months Later, the Company Sought Liquidation https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley-en/figure-04.png Figure 4: Three outcomes—Iterum liquidation, Karyopharm stress test and Theravance value exit A New Drug Launched. Seven Months Later, the Company Sought Liquidation https://drugnews.com.tw/articles/2026-09-02-post-approval-biotech-commercialization-death-valley.html https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/cover.png 圖 1｜新藥上市不是終點：收入、成本、管線與資本四個時鐘同時啟動新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後 https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-02.png 圖 2｜Iterum 七個月商業化倒數：40 萬美元收入對上 650 萬美元費用新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後 https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-03.png 圖 3｜Karyopharm 壓力測試：產品收入、現金、債務與新適應症同時倒數新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後 https://drugnews.com.tw/assets/articles/post-approval-biotech-commercialization-death-valley/figure-04.png 圖 4｜三種結局：Iterum 清算、Karyopharm 壓力測試、Theravance 價值退出新藥上市才 7 個月，公司就聲請清盤：真正的死亡谷在核准之後 https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery-en.html https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/cover.png Drugnews editorial visualization connecting a laboratory cell to a computational virtual cell for prediction followed by validation Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/figure-01.png Figure 1 | A virtual cell is a computational prototype for testing hypotheses before returning to the laboratory Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/figure-02.png Figure 2 | A stateful digital cell retains a shared state across sequential perturbations and branching experiments Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/figure-03.png Figure 3 | AIDO Cell has a prototype evidence base, while novel predictions still face wet-lab, external-replication and blind-test gates Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery-en/figure-04.png Figure 4 | The commercial value of a virtual cell depends on a closed loop among data, models, prioritized experiments and validated evidence Can New Drugs Be Tested in a Computer First? The Virtual Cell Is Here https://drugnews.com.tw/articles/2026-09-01-aido-cell-virtual-cell-drug-discovery.html https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/cover.png 實體細胞與數位細胞模型相連，呈現 AIDO Cell 先計算再驗證的 Drugnews 編輯視覺新藥能先在電腦裡試？「虛擬細胞」來了！ https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-01.png 圖 1｜細胞實驗不用做了？虛擬細胞來了！新藥能先在電腦裡試？「虛擬細胞」來了！ https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-02.png 圖 2｜一顆會記得的數位細胞：共享狀態與連續擾動新藥能先在電腦裡試？「虛擬細胞」來了！ https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-03.png 圖 3｜證據階梯：兩種原型細胞到獨立濕實驗，還差哪一步？新藥能先在電腦裡試？「虛擬細胞」來了！ https://drugnews.com.tw/assets/articles/aido-cell-virtual-cell-drug-discovery/figure-04.png 圖 4｜商業閉環：資料、模型、實驗如何互相回饋新藥能先在電腦裡試？「虛擬細胞」來了！ https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift-en.html https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/cover.png Drugnews editorial visualization of GLP-1 drugs reshaping food, beverage and service economics in luxury hotels GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue? https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/figure-01.png GLP-1 adoption was associated with lower grocery and limited-service restaurant spending, but the evidence is not a forecast of hotel revenue GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue? https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/figure-02.png Luxury hotels can redesign value through portion flexibility, zero-proof ritual, room amenities, personalization and nutrition plus strength GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue? https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/figure-03.png GLP-1 can shift value from food volume toward service redesign, wellness and new revenue pools, while evidence boundaries remain essential GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue? https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift-en/figure-04.png Taiwan hotel operators should measure portion demand, zero-proof check value, wellness repeat purchase and food waste before declaring a GLP-1 revolution GLP-1 Drugs Are Making Luxury Guests Eat Less. How Can Five-Star Hotels Protect Revenue? https://drugnews.com.tw/articles/2026-08-31-glp1-luxury-hospitality-spending-shift.html https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/cover.png GLP-1 改變五星級飯店餐飲與服務價值公式的 Drugnews 編輯視覺減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？ https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/figure-01.png GLP-1 讓高端旅客吃得更少，奢華飯店必須重新定義價值減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？ https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/figure-02.png GLP-1 的食慾與飽足訊號如何一路映射到家戶支出減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？ https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/figure-03.png 少吃不等於少收錢，高端飯店可以從份量、無酒精體驗、房內設計、個人化與營養加肌力重新設計服務減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？ https://drugnews.com.tw/assets/articles/glp1-luxury-hospitality-spending-shift/figure-04.png GLP-1 的外溢效應可能把低食量壓力轉成服務重設、新價值與新收入池減重針逼瘋五星級飯店？客人吃少了，飯店靠什麼賺？ https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3-en.html https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/cover.png Editorial visualization of avexitide blocking the GLP-1 receptor to reduce post-bariatric hypoglycemia risk Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-01.png Amylyx moved from the withdrawal of Relyvrio to a positive Phase 3 result with a GLP-1 receptor antagonist Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-02.png In post-bariatric hypoglycemia, rapid nutrient delivery can drive excessive GLP-1 signaling, an insulin surge and a glucose crash; avexitide blocks the GLP-1 receptor Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-03.png LUCIDITY enrolled 78 adults for 16 weeks and reported a 55% reduction in the combined rate of Level 2 and Level 3 hypoglycemic events Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3-en/figure-04.png Amylyx withdrew Relyvrio, acquired avexitide for $35.1 million, reported a positive Phase 3 trial and then raised approximately $500.2 million Avexitide Reduced the Composite Rate of Level 2/3 Hypoglycemia Events by 55%—and Repriced Amylyx Overnight https://drugnews.com.tw/articles/2026-08-30-amylyx-avexitide-pbh-phase3.html https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/cover.png Avexitide 阻斷 GLP-1 受體以降低減重手術後低血糖風險的編輯視覺減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！ https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/01_%E5%B0%81%E9%9D%A2_GLP1%E5%B0%8D%E8%B7%96%E9%BB%9E_%E8%82%A1%E5%83%B9%E6%9A%B4%E6%BC%B264.png Amylyx 從撤市谷底，到 GLP-1 對跖點三期成功減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！ https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/02_PBH%E6%A9%9F%E5%88%B6_avexitide%E9%98%BB%E6%96%B7GLP1%E5%8F%97%E9%AB%94.png PBH 機制：GLP-1 訊號過強，胰島素煞車踩過頭減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！ https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/03_LUCIDITY%E4%B8%89%E6%9C%9F_55percent%E8%88%87%E5%AE%89%E5%85%A8%E6%80%A7.png LUCIDITY 三期證據卡：78 人、16 週、事件減少 55% 減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！ https://drugnews.com.tw/assets/articles/amylyx-avexitide-pbh-phase3/04_3510%E8%90%AC%E7%BE%8E%E5%85%83%E6%8A%84%E5%BA%95_%E5%9B%9B%E9%81%93%E4%B8%8A%E5%B8%82%E9%97%9C%E5%8D%A1.png Amylyx 反轉時間線：撤市、抄底、三期、募資與上市關卡減重手術後，吃飯竟可能昏倒？一款新藥讓 Amylyx 暴漲 64%！ https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on-en.html https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on-en/cover.png RASONQUE is the first approved broad RAS ON inhibitor for a defined metastatic pancreatic adenocarcinoma population, not a cure claim Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on-en/figure-01.png RASolute 302 enrolled 500 patients and showed median overall survival of 13.2 versus 6.7 months and median progression-free survival of 7.2 versus 3.6 months Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on-en/figure-02.png Revolution Medicines moved from antifungal natural products to SHP2, acquired Warp Drive, sold a non-core platform, acquired EQRx cash, secured flexible financing and won FDA approval Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on-en/figure-03.png RASONQUE commercialization now depends on access and activation, safety management, real-world persistence and expansion into new indications and markets Pancreatic Cancer Finally Gets a Broad RAS(ON) Drug: Inside RASONQUE's FDA Approval https://drugnews.com.tw/articles/2026-08-29-revolution-rasonque-pancreatic-cancer-ras-on.html https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/cover.png RASONQUE 廣譜 RAS(ON) 抑制劑開啟轉移性胰臟癌新治療入口的編輯視覺胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/01_%E5%B0%81%E9%9D%A2_%E8%83%B0%E8%87%9F%E7%99%8C%E7%B5%82%E6%96%BC%E8%A2%AB%E6%92%AC%E9%96%8B%E4%B8%80%E9%81%93%E7%B8%AB.png 圖 1｜胰臟癌終於被撬開一道縫胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/02_%E8%87%A8%E5%BA%8A%E8%AD%89%E6%93%9A_%E5%85%A9%E6%A2%9D%E7%94%9F%E5%AD%98%E6%9B%B2%E7%B7%9A.png 圖 2｜兩條生存曲線，幾乎都翻倍胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/03_%E5%8D%81%E4%B8%80%E5%B9%B4%E8%BD%89%E5%90%91%E6%99%82%E9%96%93%E7%B7%9A.png 圖 3｜Revolution 十一年轉向時間線胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-rasonque-pancreatic-cancer-ras-on/04_%E5%95%86%E6%A5%AD%E5%8C%96%E5%9B%9B%E9%97%9C.png 圖 4｜藥證到手，商業化四關才開始胰臟癌終於被撬開一道縫！FDA 提前 6.5 個月批准首款廣譜 RAS 新藥 https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv-en.html https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv-en/cover-v2.png Figure 1 | Zealand monetized selected rusfertide economics before the FDA decision, while Takeda retained worldwide development and commercialization rights A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv-en/figure-03-v2.png Figure 2 | Royalty Pharma acquired Zealand's 1% global royalty and milestones; Zealand retained 0.25% on annual net sales above $1.5 billion A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv-en/figure-01-v2.png Figure 3 | Rusfertide mimics hepcidin and restricts iron availability; in VERIFY, the response without a phlebotomy indication was 76.9% versus 32.9% A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv-en/figure-02-v2.png Figure 4 | BESREMi and rusfertide are not a simple either-or choice; VERIFY allowed rusfertide on top of existing therapy, and no head-to-head trial has compared the two A New Rival for PharmaEssentia? What Zealand Actually Sold for $100 Million https://drugnews.com.tw/articles/2026-08-28-zealand-rusfertide-royalty-pharma-pv.html https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv/cover.png 圖 1｜Zealand 在 FDA 決定前將 rusfertide 的部分未來經濟權益變現；全球開發與商業化權仍由武田掌握藥華藥迎新對手？1 億美元賣分潤 https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv/figure-03.png 圖 2｜Royalty Pharma 買下 Zealand 的 1% 全球權利金與里程碑；Zealand 保留年銷售超過 15 億美元部分的 0.25% 上行權利藥華藥迎新對手？1 億美元賣分潤 https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv/figure-01.png 圖 3｜rusfertide 模擬鐵調素、限制鐵進入造血；VERIFY 第 20 至 32 週「沒有放血適應症」反應為 76.9% 對 32.9% 藥華藥迎新對手？1 億美元賣分潤 https://drugnews.com.tw/assets/articles/zealand-rusfertide-royalty-pharma-pv/figure-02.png 圖 4｜BESREMi 與 rusfertide 並非簡單二選一；VERIFY 可疊加干擾素等現有治療，且尚無兩者頭對頭試驗藥華藥迎新對手？1 億美元賣分潤 https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels-en.html https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/cover.png DNA synthesis, an automated wet lab and AI model feedback connected in a drug-discovery workflow DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/figure-01.png Figure 1 | DNA synthesis, an automated wet lab and AI model feedback form a complete workflow; demand growth does not mean unit value and industry moat rise with it DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/figure-02.png Figure 2 | N, P and V separate candidate volume, physical validation rate and value per experiment; sequence count is not the only variable DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/figure-03.png Figure 3 | Changes in cost, waste, turnaround time and capacity across Twist’s roughly one-million-oligo, femtomole-scale platform DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels-en/figure-04.png Figure 4 | DNA synthesis, protein expression, characterization, functional testing and model feedback form the full AI wet-lab loop DNA Is Not the Nvidia of AI Drug Discovery, At Least Not Yet https://drugnews.com.tw/articles/2026-08-27-twist-dna-ai-drug-discovery-shovels.html https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/cover.png DNA 合成、自動化濕實驗室與 AI 模型回饋構成的藥物發現工作流 DNA 不是 AI 製藥的輝達，至少現在還不是 https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/figure-01.png 圖 1｜DNA 合成、自動化濕實驗室與 AI 模型回饋構成完整工作流；需求成長不等於單位價值或產業壁壘同步上升 DNA 不是 AI 製藥的輝達，至少現在還不是 https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/figure-02.png 圖 2｜N、P、V 分別代表候選序列數、物理驗證率與單次實驗價值；序列數量不是唯一決定變數 DNA 不是 AI 製藥的輝達，至少現在還不是 https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/figure-03.png 圖 3｜Twist 約 100 萬條 oligo、飛莫耳規模平台的成本、廢棄物、作業時間與產能變化 DNA 不是 AI 製藥的輝達，至少現在還不是 https://drugnews.com.tw/assets/articles/twist-dna-ai-drug-discovery-shovels/figure-04.png 圖 4｜DNA 合成、蛋白質表現、特性分析、功能測試與模型回饋構成完整 AI wet-lab 迴圈 DNA 不是 AI 製藥的輝達，至少現在還不是 https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9-en.html https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/cover.png Lipfendra daily oral dosing and Leqvio infrequent injection as competing PCSK9 treatment routines Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/figure-01.png Figure 1 | Lipfendra brings oral dosing to a PCSK9 market built around injections, but it does not make injectable therapies obsolete Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/figure-02.png Figure 2 | Lipfendra blocks PCSK9 from binding the LDL receptor, preserving receptors on the liver-cell surface Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/figure-03.png Figure 3 | Daily oral therapy, infrequent provider-administered dosing and antibodies with cardiovascular outcomes evidence represent different adherence and evidence models Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9-en/figure-04.png Figure 4 | Oral PCSK9 therapy must clear four gates: LDL-C lowering, cardiovascular outcomes, physician and payer access, and Taiwan approval and reimbursement Merck’s Oral PCSK9 Drug Enters an Injectable Market: Who Really Loses? https://drugnews.com.tw/articles/2026-08-26-merck-lipfendra-oral-pcsk9.html https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/cover.png 默沙東 Lipfendra 每日口服與 Leqvio 低頻注射兩條 PCSK9 降脂路徑默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-01.png 圖 1｜默沙東把原本由注射主導的 PCSK9 靶點做成每日口服藥，但口服不等於針劑退場默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-02.png 圖 2｜Lipfendra 阻止 PCSK9 與 LDL 受體結合，讓受體留在肝細胞表面清除更多 LDL-C 默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-03.png 圖 3｜每日口服、院所低頻注射與已有硬終點證據的 PCSK9 單抗，是三套不同的依從性與證據邏輯默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/assets/articles/merck-lipfendra-oral-pcsk9/figure-04.png 圖 4｜口服 PCSK9 從 LDL-C 降幅走到真實市場，仍要通過心血管硬終點、醫師與支付准入、台灣核准與健保四道門默沙東口服藥殺進「降膽固醇針」市場，誰會被搶走？ https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en.html https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/cover.png Figure 1 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image2.png Figure 2 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image3.png Figure 3 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image4.png Figure 4 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image5.png Figure 5 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image6.png Figure 6 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology-en/image7.png Figure 7 The Stronger the Backbone, the More Valuable the Missing Layer: Can Anbogen's ABT-301 Enter the Next Wave of Oncology BD? https://drugnews.com.tw/articles/2026-08-25-anbogen-abt-301-combination-layer-tokyo-comparative-oncology.html https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/cover.png 圖1 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image2.png 圖2 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image3.png 圖3 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image4.png 圖4 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image5.png 圖5 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image6.jpg 圖6 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/assets/articles/anbogen-abt-301-combination-layer-tokyo-comparative-oncology/image7.png 圖7 主藥越強，旁邊缺的那一層越值錢：安邦ABT-301能否進入下一輪腫瘤BD名單？ https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger-en.html https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/cover.png A radiopharma loop connecting isotope production, timed distribution, PSMA PET imaging, targeted treatment and follow-up Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-01.webp Figure 1 | Curium contributes isotope, manufacturing, distribution and therapy capabilities; Lantheus contributes U.S. diagnostics and hospital access Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-02.webp Figure 2 | Radiopharma runs on a timed chain from isotope production and labeling through quality control, shielded delivery and hospital use Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-03.webp Figure 3 | Find, Fight, Follow: use PSMA PET to identify a patient, deliver targeted radioligand therapy and continue imaging-based follow-up Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger-en/figure-04.webp Figure 4 | Radiopharma M&A is moving from buying a single pipeline to integrating isotope supply, manufacturing, distribution, diagnostics, therapy and hospital channels Curium and Lantheus Agree to an Up-to-$8 Billion Merger: Radiopharma Becomes a Full-Stack Business https://drugnews.com.tw/articles/2026-08-24-curium-lantheus-definitive-merger.html https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/cover.png 核素製造、放射性藥物、冷鏈配送、PET 診斷與精準治療串成一體的核藥產業鏈核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額 https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-01.webp 圖 1｜Curium 的核素、製造、配送與治療端，和 Lantheus 的美國診斷產品與醫院網絡形成互補核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額 https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-02.webp 圖 2｜核藥從同位素生產、標記、品管、屏蔽配送到院端使用，每一步都受到半衰期限制核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額 https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-03.webp 圖 3｜Find、Fight、Follow：先用 PSMA PET 找到患者，再以靶向核藥治療，最後持續影像追蹤核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額 https://drugnews.com.tw/assets/articles/curium-lantheus-definitive-merger/figure-04.webp 圖 4｜核藥併購邏輯從購買單一管線，升級為整合同位素、製造、配送、診斷、治療與院端通路核藥史上最大併購：Curium 與 Lantheus 合併，改寫的不只是交易金額 https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026-en.html https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/cover.png How Big Pharma looks for biotech assets whose clinical risk is falling before value is fully priced Who Could Be Big Pharma's Next Major Biotech Acquisition? https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-01.png Figure 1 | The new acquisition standard combines human proof of concept, platform expansion, strategic fit and value that has not yet been fully priced Who Could Be Big Pharma's Next Major Biotech Acquisition? https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-02.png Figure 2 | Alkermes has advanced alixorexton into global Phase 3 while using orexin biology to explore a broader neuroscience platform Who Could Be Big Pharma's Next Major Biotech Acquisition? https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-03.png Figure 3 | Following the Avidity and Forte transactions, Dyne's muscle-delivery platform and First Tracks' CD122 program are the two routes most exposed to repricing Who Could Be Big Pharma's Next Major Biotech Acquisition? https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026-en/figure-04.png Figure 4 | Legend, Sail, Pharmosa and Lin BioScience illustrate four acquisition languages: commercial revenue, next-generation platforms, option-based positioning and late-stage specialist assets Who Could Be Big Pharma's Next Major Biotech Acquisition? https://drugnews.com.tw/articles/2026-08-23-big-pharma-biotech-ma-next-targets-2026.html https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/cover.png Big Pharma 如何尋找臨床風險剛下降、價值尚未完全定價的生技資產 Biotech 下一筆重磅併購，會落在誰身上？ https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-01.png 圖 1｜大型藥廠的新併購標準，落在人體概念驗證、平台外延、買方契合與尚未完全定價的交會處 Biotech 下一筆重磅併購，會落在誰身上？ https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-02.png 圖 2｜Alkermes 的 alixorexton 已進入全球 Phase 3，並從嗜睡症與特發性嗜睡症向更大的中樞神經市場延伸 Biotech 下一筆重磅併購，會落在誰身上？ https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-03.png 圖 3｜Avidity 與 Forte 交易後，Dyne 的肌肉靶向核酸遞送與 First Tracks 的 CD122 免疫調節成為下一波觀察重點 Biotech 下一筆重磅併購，會落在誰身上？ https://drugnews.com.tw/assets/articles/big-pharma-biotech-ma-next-targets-2026/figure-04.png 圖 4｜Legend、Sail 與台灣國邑、仁新的案例，呈現成熟收入、下一代平台、提前卡位與後期專科資產的不同交易語言 Biotech 下一筆重磅併購，會落在誰身上？ https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs-en.html https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/cover.png BeOne places four bets on RAS through regional rights, combinations and a global Phase 3 BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-01.png Figure 1 | The four RAS(ON) programs span multi-selective, G12D, G12C and G12V strategies, with maturity ranging from NDA review to early clinical development BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-02.png Figure 2 | BGB-58067 and BG-T187 may be paired with daraxonrasib or zoldonrasib, but fixed combinations, tumor types, doses and timing remain undisclosed BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs-en/figure-03.png Figure 3 | The collaboration covers four RAS(ON) programs, selected Asian markets and one global registrational Phase 3, while the country list, economics and Phase 3 program remain undisclosed BeOne Bets on Four RAS Drugs: The Real Asset Is Development Optionality https://drugnews.com.tw/articles/2026-08-22-revolution-medicines-beone-four-ras-programs.html https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/cover.png 百濟神州一次接進四款 RAS 新藥、兩種聯用與一項全球三期百濟神州一口氣押上 4 款 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-01.png 圖 1｜四款 RAS(ON) 資產涵蓋多重選擇性、G12D、G12C 與 G12V，成熟度從 NDA 審查到早期臨床百濟神州一口氣押上 4 款 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-02.png 圖 2｜BGB-58067 與 BG-T187 可望搭配 daraxonrasib 或 zoldonrasib，但固定配對、癌別、劑量與時程尚未公布百濟神州一口氣押上 4 款 RAS 新藥 https://drugnews.com.tw/assets/articles/revolution-medicines-beone-four-ras-programs/figure-03.png 圖 3｜合作涵蓋四款 RAS(ON) 資產、部分亞洲市場及一項全球註冊三期，但國家清單、財務條款與三期落點仍未完整披露百濟神州一口氣押上 4 款 RAS 新藥 https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma-en.html https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/cover.png Moderna intismeran Phase 3 melanoma result and the stock's 176.97 percent one-day gain Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-02.png Figure 1 | INTerpath-001 met the RFS and DMFS endpoints, but hazard ratios, curves, absolute effects and overall-survival evidence remain undisclosed Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-01.png Figure 2 | Each patient's path runs from tumor and blood sampling through sequencing, neoantigen selection, mRNA manufacture, quality release and administration Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma-en/figure-03.png Figure 3 | Commercializing a personalized mRNA medicine requires four connected systems: prediction, manufacturing, patient-level quality release, and cold-chain clinical delivery Moderna Surges 176.97% After Its Personalized Cancer Vaccine Clears a Phase 3 Test https://drugnews.com.tw/articles/2026-08-21-moderna-merck-intismeran-phase3-melanoma.html https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/cover.png 莫德納 intismeran 個人化癌症疫苗第三期達標與 176.97% 單日漲幅再見癌症？癌症疫苗來了！莫德納單日暴漲176.97% https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-02.png 圖 1｜INTerpath-001 第三期同時達到 RFS 與 DMFS 終點，但風險比、存活曲線與總生存期仍未完整揭露再見癌症？癌症疫苗來了！莫德納單日暴漲176.97% https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-01.png 圖 2｜每位患者都要經過腫瘤與血液取樣、定序、新抗原挑選、mRNA 製造、質控及回院給藥再見癌症？癌症疫苗來了！莫德納單日暴漲176.97% https://drugnews.com.tw/assets/articles/moderna-merck-intismeran-phase3-melanoma/figure-03.png 圖 3｜個人化 mRNA 藥物商業化需要新抗原預測、製造、個別批次質控與冷鏈臨床交付四套系統再見癌症？癌症疫苗來了！莫德納單日暴漲176.97% https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly-en.html https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/cover.png BMS, Lilly and NVIDIA illustrate Big Pharma's AI infrastructure arms race NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-01.png Figure 1 | Big Pharma's 2026 AI commitments span compute, cloud, enterprise agents and laboratory infrastructure; announced spending limits and capacity are not clinical outcomes NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-02.png Figure 2 | The evidence ladder runs from compute and agents through wet-lab work and candidate nomination to clinical trials; a small early Phase 1 review cannot be extrapolated into approval probability NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly-en/figure-03.png Figure 3 | Taiwan sits across the AI infrastructure chain, but participation in NVIDIA's ecosystem is not evidence of a specific BMS or Roche order NVIDIA Enters Pharma: BMS Readies 576 GPUs as Lilly Commits Up to $1 Billion https://drugnews.com.tw/articles/2026-08-20-big-pharma-ai-arms-race-nvidia-bms-lilly.html https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly/cover.png BMS、禮來與 NVIDIA 推動大藥廠 AI 研發基礎設施競賽輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元 https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly/figure-01.png 圖 1｜2026 年大藥廠 AI 軍備表；金額多為多年投入上限，設備規模不等於臨床成功輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元 https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly/figure-02.png 圖 2｜AI 製藥從算力、代理人與濕實驗走到候選藥及臨床驗證；一期小樣本早期回顧不能外推上市成功率輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元 https://drugnews.com.tw/assets/articles/big-pharma-ai-arms-race-nvidia-bms-lilly/figure-03.png 圖 3｜台灣位於 NVIDIA AI 基礎設施鏈上，但生態系關係不等於取得 BMS 或 Roche 的特定訂單輝達殺進製藥業！BMS 搶 576 顆 GPU，禮來砸 10 億美元 https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king-en.html https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/cover.png Skyrizi closing to within $74 million of Humira's quarterly revenue record in an autoimmune product relay Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King? https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-01.png Figure 1 | Humira's historic quarterly peak and Skyrizi's Q2 2026 revenue are now separated by only $74 million Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King? https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-02.png Figure 2 | Skyrizi and ICOTYDE use very different regimens, and their label results come from separate trials rather than a head-to-head comparison Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King? https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king-en/figure-03.png Figure 3 | Depth of response, treatment burden, comorbidity and safety, and patient access jointly determine the next autoimmune leader Just $74 Million Short: Can Skyrizi Succeed Humira as the Autoimmune Drug King? https://drugnews.com.tw/articles/2026-08-19-skyrizi-humira-autoimmune-drug-king.html https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/cover.png Skyrizi 距 Humira 單季收入紀錄只差 7,400 萬美元的自體免疫接力圖解 55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？ https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-01.png 圖 1｜Humira 與 Skyrizi 的歷史單季收入紀錄只差 7,400 萬美元 55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？ https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-02.png 圖 2｜Skyrizi 與 ICOTYDE 的療程及標籤試驗結果來自不同研究，不能直接判定誰贏 55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？ https://drugnews.com.tw/assets/articles/skyrizi-humira-autoimmune-drug-king/figure-03.png 圖 3｜自體免疫市場的決勝因素包括療效深度、治療負擔、共病安全與支付可近性 55 億美元只差一步：Skyrizi 要接棒 Humira 當自體免疫藥王？ https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king-en.html https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/cover-editorial.jpg A weekly obesity-treatment injection pen and sculptural peptide molecule representing a product relay Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-01.png Figure 1 | Tirzepatide now anchors both diabetes and obesity revenue, making concentration the central strategic question Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-02.png Figure 2 | Lilly is trying to turn tirzepatide cash flow into a product relay spanning oral GLP-1 and a next-generation triple agonist Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-03.png Figure 3 | Lilly is using tirzepatide cash flow to buy options in sleep, in vivo CAR-T, vaccines and psychiatric disease Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king-en/figure-04.png Figure 4 | Caliway's CBL-514 program is a research read-through to the GLP-1 era, not evidence of a Lilly supply-chain relationship Eli Lilly Sold $23 Billion in One Quarter. Why Is It Still Rushing to Buy the Next Drug King? https://drugnews.com.tw/articles/2026-08-18-eli-lilly-tirzepatide-next-drug-king.html https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/cover-editorial.jpg 一支減重治療注射筆與代表產品接棒的胜肽分子視覺一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-01.png 圖1｜禮來第二季營收與 tirzepatide 收入集中度圖解一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-02.png 圖2｜Foundayo 與 retatrutide 接棒 tirzepatide 的產品路徑圖一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-03.png 圖3｜禮來以併購尋找第二座成長山脈的資本配置圖一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/assets/articles/eli-lilly-tirzepatide-next-drug-king/figure-04.png 圖4｜康霈 CBL-514 與 tirzepatide 研究邊界示意圖一季狂賣 230 億美元，禮來卻急著買下一個藥王 https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization-en.html https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/cover.png Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? homepage image Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-01.png Figure 1 | Iovance's Q2 rebound shows that TIL commercialization is starting to move, but profitability is not yet proven Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-02.png Figure 2 | TIL therapy is a relay from referral and tumor harvest to manufacturing, hospitalization, infusion and reimbursement Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-03.png Figure 3 | The hospital is part of the product: TIL commercialization depends on ICU readiness, payer approval and standardized execution Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization-en/figure-04.png Figure 4 | The next decade will depend on conversion rate, manufacturing scale, hospital execution, reimbursement and confirmatory data Revenue Jumped 39%, Yet Iovance Still Lost $47 Million: Can Cancer Cell Therapy Become a Business? https://drugnews.com.tw/articles/2026-08-17-iovance-amtagvi-til-commercialization.html https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/cover.png Iovance 第二季營收反彈與 Amtagvi 商業化進展圖解營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？ https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-01.png 圖1｜Iovance 第二季營收反彈與 Amtagvi 商業化進展圖解營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？ https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-02.png 圖2｜TIL 療法從腫瘤取樣、製造、輸注到支付的一條接力流程營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？ https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-03.png 圖3｜Amtagvi 從工廠到病房的四個營運堵點營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？ https://drugnews.com.tw/assets/articles/iovance-amtagvi-til-commercialization/figure-04.png 圖4｜個人化癌症細胞療法下一個十年的勝負關鍵營收跳增 39%，還是虧了 4,700 萬美元：癌症細胞療法翻身了？ https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen-en.html https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-01.png Figure 1 | The obesity drug shakeout accelerates as ordinary programs lose their ticket to the GLP-1 market Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses? https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-02.png Figure 2 | The entry ticket for the next phase of GLP-1 competition spans efficacy, safety, convenience, comorbidity benefit, manufacturing and access Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses? https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-03.png Figure 3 | Pfizer, Roche and Amgen are concentrating resources on obesity assets that may still break through Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses? https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen-en/figure-04.png Figure 4 | Taiwan's adjacent opportunities: Caliway targets adipose remodeling and weight maintenance while ANYA tests the oral-peptide barrier Pfizer Paid Billions for Obesity Assets. Is It Already Cutting Its Losses? https://drugnews.com.tw/articles/2026-08-16-obesity-drug-shakeout-pfizer-roche-amgen.html https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-01.png 圖1｜減重藥淘汰賽加速，普通玩家在 GLP-1 下半場開始出局百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？ https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-02.png 圖2｜GLP-1 下半場的門票：療效、安全、便利性、共病效益與製造支付能力百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？ https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-03.png 圖3｜Pfizer、Roche 與 Amgen 集中資源推進真正有機會突圍的核心減重資產百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？ https://drugnews.com.tw/assets/articles/obesity-drug-shakeout-pfizer-roche-amgen/figure-04.png 圖4｜台灣相鄰機會：康霈切入脂肪重塑與減重維持，奧孟亞挑戰口服胜肽門檻百億美元搶來的減肥藥，輝瑞冤大頭又丟掉了？ https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility-en.html https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/cover-v2.png After a roughly US$2 billion acquisition, camlipixant encountered a Phase 3 reproducibility test GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-01.svg Figure 1 | The same drug and dose produced different pivotal outcomes in CALM-1 and CALM-2. GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-02.svg Figure 2 | SOOTHE created a strong Phase 2 signal; the US$2 billion acquisition purchased a late-stage hypothesis, not a guaranteed approval. GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-03.svg Figure 3 | Phase 3 retests an early signal across a larger, more heterogeneous population, longer follow-up and reproducibility requirements. GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility-en/figure-04.svg Figure 4 | GSK stopped refractory chronic cough development, while the Phase 2b BALANCE study in IBS continues. GSK's US$2 Billion Cough-Drug Bet Hit a Phase 3 Reproducibility Wall https://drugnews.com.tw/articles/2026-08-15-gsk-camlipixant-calm-phase3-reproducibility.html https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/cover-v2.png 約 20 億美元收購後，camlipixant 在第三期面臨重現性考驗 GSK 砸 20 億美元買止咳新藥，三期卻翻車！ https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-01.png 圖1｜同一個藥、同一劑量，CALM-1 與 CALM-2 得到不同的第三期結果 GSK 砸 20 億美元買止咳新藥，三期卻翻車！ https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-02.png 圖2｜SOOTHE 二期訊號與約 20 億美元收購：買進的是後期假設，不是確定核准 GSK 砸 20 億美元買止咳新藥，三期卻翻車！ https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-03.png 圖3｜第三期不是放大二期，而是用更大族群、更長追蹤重新檢驗結果能否重現 GSK 砸 20 億美元買止咳新藥，三期卻翻車！ https://drugnews.com.tw/assets/articles/gsk-camlipixant-calm-phase3-reproducibility/figure-04.png 圖4｜RCC 開發停止，BALANCE 第二期仍繼續：不同適應症不能直接外推 GSK 砸 20 億美元買止咳新藥，三期卻翻車！ https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket-en.html https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/cover.png Intelligene uses EV and LNP RNA delivery platforms to target lung and airway diseases beyond the liver. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/cover-1400.webp Intelligene is building a nanorocket inside the human body for the second half of oligonucleotide therapeutics. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-01.png Figure 1 | The first half of oligonucleotide therapeutics is sequence design; the second half is delivery beyond the liver. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-02.png Figure 2 | Commercial RNA medicines, hepatitis B functional-cure data, and extrahepatic delivery are reshaping the small-RNA opportunity. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-03.png Figure 3 | Organ-level delivery difficulty is beginning to reprice RNA platform companies. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-04.png Figure 4 | Intelligene is using lung and airway programs to build an EV and LNP RNA delivery platform. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket-en/figure-05.png Figure 5 | Intelligene's next valuation variables include preclinical data, IND progress, Phase 1 entry, CMC execution, and international partnerships. This Taiwanese Biotech Is Building a Nanorocket Inside the Human Body https://drugnews.com.tw/articles/2026-08-13-intelligene-rna-delivery-nanorocket.html https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/cover.png 智新生物以 EV 與 LNP RNA 遞送平台，挑戰肺部與呼吸道肝外遞送這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/cover-1400.webp 智新生物打造人體內奈米火箭，挑戰小核酸下半場的遞送問題這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-01.png 圖1｜小核酸藥物的上半場是序列設計，下半場是遞送能否抵達病灶這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-02.png 圖2｜小核酸藥物從商業化產品、慢性 B 肝功能性治癒訊號到肝外遞送新戰場這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-03.png 圖3｜肝臟之外的器官遞送難度，正在重新定價 RNA 平台公司這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-04.png 圖4｜智新生技以肺部與呼吸道為起點，打造 EV 與 LNP RNA 遞送平台這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/assets/articles/intelligene-rna-delivery-nanorocket/figure-05.png 圖5｜智新生技的下一階段估值變數，包括臨床前資料、IND、Phase 1、CMC 與國際合作這家台灣Biotech正在打造人體內奈米火箭 https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure-en.html https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/cover.png Figure 1 | ZEUS enrolled more than 6,300 patients; inflammation markers fell, but three-point MACE did not improve. Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-01.png Figure 1 | ZEUS enrolled more than 6,300 patients; inflammation markers fell, but three-point MACE did not improve. Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-02.png Figure 2 | RESCUE and ZEUS answered different questions: biomarker response is not outcome proof. Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-03.png Figure 3 | Risk markers, pharmacodynamic markers, and surrogate endpoints sit on different evidence layers. Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure-en/figure-04.png Figure 4 | What ZEUS tells us, what remains unknown, and what investors should not extrapolate. Novo Nordisk’s 6,300-Patient ZEUS Failure: A Textbook Lesson in Translational Risk https://drugnews.com.tw/articles/2026-08-13-ziltivekimab-zeus-mace-phase3-failure.html https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/cover.png 圖1｜ZEUS 超過 6,300 人、HR 0.99，發炎指標下降但三點 MACE 未降低諾和諾德大三期慘敗！6,300 人的教科書級教訓 https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-01.png 圖1｜ZEUS 超過 6,300 人、HR 0.99，發炎指標下降但三點 MACE 未降低諾和諾德大三期慘敗！6,300 人的教科書級教訓 https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-02.png 圖2｜RESCUE 與 ZEUS 回答不同問題，二期 biomarker 不能直接外推三期硬終點諾和諾德大三期慘敗！6,300 人的教科書級教訓 https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-03.png 圖3｜風險標誌物、藥效學標誌物與替代終點是三種不同證據層級諾和諾德大三期慘敗！6,300 人的教科書級教訓 https://drugnews.com.tw/assets/articles/ziltivekimab-zeus-mace-phase3-failure/figure-04.png 圖4｜ZEUS 目前已知、未知與不能外推的結論邊界諾和諾德大三期慘敗！6,300 人的教科書級教訓 https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd-en.html https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/cover.png Bio Genesis Mission rebuilds the drug-development feedback loop with AI Can $1.2 Billion Help AI Double the Pace of Drug R&D? https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/figure-01.png Figure 1 | Bio Genesis aims to connect governed biomedical data, AI supercomputing, hypothesis generation, automated experiments, and clinical evidence in a repeatable R&D loop. Can $1.2 Billion Help AI Double the Pace of Drug R&D? https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/figure-02.png Figure 2 | The six Bio Genesis missions span complex biological systems, manufacturing scale-up, biological threats, childhood cancer, translational medicine, and chronic disease. AI is one shared layer of the infrastructure. Can $1.2 Billion Help AI Double the Pace of Drug R&D? https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/figure-03.png Figure 3 | The $1.2 billion, $5 billion, and $800 million figures refer to NIH resources, the broader Genesis Mission, and partner commitments, respectively. They cannot be added together or treated as one fund. Can $1.2 Billion Help AI Double the Pace of Drug R&D? https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd-en/figure-04.png Figure 4 | In Taiwan, digital pathology and clinical-data governance form one capability coordinate, while genomics and multi-omics form another. Capability alignment does not imply a US government contract. Can $1.2 Billion Help AI Double the Pace of Drug R&D? https://drugnews.com.tw/articles/2026-08-12-bio-genesis-mission-ai-drug-rd.html https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/cover.png 美國 Bio Genesis Mission 以 AI 重接新藥研發回饋迴路美國砸 12 億美元，想用 AI 把新藥研發快一倍！ https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/figure-01.png 圖1｜Bio Genesis Mission 想把生醫資料、AI 超算、假說、自動化實驗與臨床證據接成可反覆驗證的研發閉環。美國砸 12 億美元，想用 AI 把新藥研發快一倍！ https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/figure-02.png 圖2｜Bio Genesis 的六項任務涵蓋複雜生物系統、製造放大、生物威脅、兒童癌症、藥物轉譯與慢性病；AI 只是共同底座的一層。美國砸 12 億美元，想用 AI 把新藥研發快一倍！ https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/figure-03.png 圖3｜12 億、50 億與 8 億美元分屬 NIH、整體 Genesis Mission 與產業夥伴承諾三種不同口徑，不能相加或視為同一基金。美國砸 12 億美元，想用 AI 把新藥研發快一倍！ https://drugnews.com.tw/assets/articles/bio-genesis-mission-ai-drug-rd/figure-04.png 圖4｜台灣可觀察臨床資料治理與醫療 AI，以及基因體與精準醫療兩個能力座標；能力對位不等於取得美方合約。美國砸 12 億美元，想用 AI 把新藥研發快一倍！ https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone-en.html https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/cover.png ABT-301 epigenetic remodeling opens an immune-excluded solid tumor to cytotoxic T cells After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-01.png Figure 1 | Three barriers have constrained HDAC inhibitors in solid tumors for two decades: safety and combinability, a narrow therapeutic window, and the failure of early responses to consistently translate into PFS and OS. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-02.png Figure 2 | Chidamide has delivered two solid-tumor proof points: CAPability-01 achieved a 44% ORR in MSS metastatic colorectal cancer, while HBI-8000 plus nivolumab met the primary PFS endpoint in global Phase III melanoma. Hematologic toxicity and combination burden remain key points of comparison. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-03.png Figure 3 | ABT-301’s differentiation thesis links HDAC3 targeting, immune-microenvironment remodeling, and resistance biology to human exposure and, ultimately, combination-treatment validation. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-04.png Figure 4 | Phase I established the human foundation for ABT-301 — safety, preliminary activity, target engagement, and a workable dose range — but not yet comparative proof. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-05.png Figure 5 | The pMMR colorectal cancer triplet creates four sequential value inflection points: combinability, reproducible efficacy, durability, and human mechanistic validation — the evidence needed to determine whether ABT-301 can become a true combination backbone. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone-en/figure-06.png Figure 6 | ABT-301’s value-unlocking path: MSS colorectal cancer sets the valuation floor; pancreatic and brain tumors add cross-tumor optionality; and repeatable success with multiple partner therapies is what ultimately supports a platform premium. Market figures are shown for demand context only. After 20 Years, Have HDAC Inhibitors Finally Found Their Role? Why ABT-301 Could Become a Next-Generation Combination Backbone https://drugnews.com.tw/articles/2026-08-11-anbogen-abt301-next-generation-hdaci-backbone.html https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/cover.png ABT-301透過表觀遺傳重塑，讓免疫細胞進入原本排斥免疫的實體腫瘤 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-01.png 圖1｜HDAC抑制劑二十年真正卡住的三道牆：安全性與可組合性、治療窗口太窄，以及早期反應無法穩定轉化為無惡化存活與整體存活。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-02.png 圖2｜Chidamide（西達本胺）完成兩項實體瘤驗證：CAPability-01在MSS轉移性大腸直腸癌取得44%客觀緩解率；HBI-8000加nivolumab則在黑色素瘤全球第三期達成主要無惡化存活終點，但骨髓毒性與聯用負擔仍需持續比較。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-03.png 圖3｜ABT-301的差異化證據鏈：由HDAC3標靶、免疫微環境與抗藥路徑，逐步連到人體暴露與聯合治療驗證。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-04.png 圖4｜ABT-301第一期人體訊號：已建立安全性、初步活性與治療窗口的推進依據，但尚未形成比較性證據。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-05.png 圖5｜pMMR大腸直腸癌三聯試驗的四階段評估：先證明可組合性，再看療效、持久性與人體機制，決定ABT-301能否升級為聯合治療骨幹。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/assets/articles/anbogen-abt301-next-generation-hdaci-backbone/figure-06.png 圖6｜ABT-301的價值解鎖路徑：MSS大腸癌建立資產底價，胰臟癌與腦腫瘤提供跨癌種選擇權，多種搭配藥物重現後才形成平台溢價；圖中市場數字僅作需求估算。 20年後，HDAC抑制劑終於找到真正的位置？ABT-301能否成為下一代聯合治療骨幹 https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1.html https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/cover.png 專利懸崖倒數，大藥廠用交易連結研發資產與商業化時間禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！ https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-01.png 禮來領頭，大藥廠半年豪砸 1,300 億美元，真正買的是時間禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！ https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-03.png BioSpace 與 IQVIA 對 2026 年上半年生技製藥併購的不同統計口徑禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！ https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-02.png 專利懸崖如何推動大藥廠收購臨床階段資產以換取開發時間禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！ https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1/figure-04.png 公告金額必須拆解為前期現金、股權價值、企業價值、或有價值權、里程碑與交割條件禮來領頭，大藥廠半年豪砸 1,300 億美元搶時間！ https://drugnews.com.tw/articles/2026-08-10-biopharma-ma-buying-time-2026h1-en.html https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/cover.png A biopharma transaction links research assets with the time needed to reach commercialization $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-01.png Lilly leads as large drugmakers spend 130 billion dollars in six months to buy time $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-03.png Different BioSpace and IQVIA methodologies for biopharma M&A in the first half of 2026 $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-02.png How the patent cliff drives large drugmakers to acquire clinical-stage assets and save development time $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/biopharma-ma-buying-time-2026h1-en/figure-04.png An announced deal value must be separated into upfront cash, equity value, enterprise value, CVRs, milestones and closing conditions $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch-en.html https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/cover.png Scientific visualization of an oral IL-23R peptide and its immune receptor J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables? https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-01.png ICOTYDE enters the high-efficacy oral psoriasis market J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables? https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-02.png Prescription volume, patient counts, prescriber reach, and insurance coverage are demand signals, not a complete revenue answer J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables? https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-03.png The one-year maintenance result must be read using the correct responder denominator J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables? https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch-en/figure-04.png The commercial follow-up for ICOTYDE centers on paid prescriptions, refill persistence, access quality, and long-term outcomes J&J's Oral Psoriasis Drug Logged 18,000 Prescriptions in Its First Full Quarter. Is It Coming for Injectables? https://drugnews.com.tw/articles/2026-08-09-icotyde-oral-il23r-launch.html https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/cover.png 口服 IL-23R 胜肽與免疫受體的藥物開發主視覺嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？ https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-01.png ICOTYDE 進入口服高療效乾癬市場嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？ https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-02.png 上市初期處方、病人、開方者與保險覆蓋，是需求訊號而非完整收入答案嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？ https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-03.png 解讀 ICOTYDE 一年療效時，必須先看清楚分析分母嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？ https://drugnews.com.tw/assets/articles/icotyde-oral-il23r-launch/figure-04.png ICOTYDE 商業化後續要看付費處方、續方留存、保險品質與長期結果嬌生口服藥首季 1.8 萬張處方，針劑飯碗要被搶了？ https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling-en.html https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/cover.png What it takes for a biotech to decline a sale Why These Four Biotechs Can Afford Not to Sell https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/figure-01.png Five capabilities that determine whether a biotech can remain independent Why These Four Biotechs Can Afford Not to Sell https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/figure-03.png How Revolution Medicines used structured financing to retain control while sharing future economics Why These Four Biotechs Can Afford Not to Sell https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/figure-02.png Four biotechs at four different stages of independence Why These Four Biotechs Can Afford Not to Sell https://drugnews.com.tw/assets/articles/biotech-independence-not-selling-en/figure-04.png Five questions to test whether a biotech can afford to remain independent Why These Four Biotechs Can Afford Not to Sell https://drugnews.com.tw/articles/2026-08-08-biotech-independence-not-selling.html https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/cover.png Biotech 不賣給大藥廠的五個條件不賣給大藥廠，4 家生技公司憑什麼自己做大？ https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-01.png 不賣給大藥廠的五個條件：產品證據、現金引擎、第二曲線、全球執行與融資選項不賣給大藥廠，4 家生技公司憑什麼自己做大？ https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-02.png 四家公司走在不同的獨立經營階段不賣給大藥廠，4 家生技公司憑什麼自己做大？ https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-03.png Revolution Medicines 以融資保留控制權，同時承擔 15 年權利金與債務成本不賣給大藥廠，4 家生技公司憑什麼自己做大？ https://drugnews.com.tw/assets/articles/biotech-independence-not-selling/figure-04.png 判斷 Biotech 是否有不賣資格的五個問題不賣給大藥廠，4 家生技公司憑什麼自己做大？ https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition.html https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/cover.png argenx 從 VYVGART 的單品成功走向 FB102 平台能力考試 22 億美元，買下一個自體免疫藥王？ https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-01.png argenx 以 22 億美元收購 Forte、把 FB102 納入免疫管線的交易考題 22 億美元，買下一個自體免疫藥王？ https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-02.png VYVGART 現金流如何支撐 argenx 收購 FB102 22 億美元，買下一個自體免疫藥王？ https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-03.png FB102 的 CD122、IL-2 與 IL-15 作用邊界 22 億美元，買下一個自體免疫藥王？ https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition/figure-04.png FB102 從兩組 Phase 1b 訊號走向 Phase 2 與長期安全驗證的證據階梯 22 億美元，買下一個自體免疫藥王？ https://drugnews.com.tw/articles/2026-08-07-argenx-forte-fb102-acquisition-en.html https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/cover.png argenx moves from VYVGART commercial scale to an early-stage FB102 platform test $2.2 Billion for the Next Autoimmune Blockbuster? https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/figure-01.png argenx proposes to acquire Forte and the early-stage anti-CD122 antibody FB102 for $2.2 billion $2.2 Billion for the Next Autoimmune Blockbuster? https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/figure-02.png VYVGART sales and argenx liquidity finance a test of whether the company can repeat its development playbook with FB102 $2.2 Billion for the Next Autoimmune Blockbuster? https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/figure-03.png FB102 targets CD122, the shared beta subunit of IL-2 and IL-15 receptors, while the long-term immune safety window remains unproven $2.2 Billion for the Next Autoimmune Blockbuster? https://drugnews.com.tw/assets/articles/argenx-forte-fb102-acquisition-en/figure-04.png The evidence ladder for FB102 runs from two Phase 1b signals to Phase 2 replication, larger studies and long-term safety $2.2 Billion for the Next Autoimmune Blockbuster? https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market-en.html https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/cover.png Hair follicles, the next-generation hair-loss market, and AH-001's topical androgen-receptor degradation mechanism Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-01.png Veradermics Study 302 hair-count and patient-reported outcomes Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-02.png Global competitive landscape for next-generation hair-loss drugs Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-03.png Evolution from follicle stimulation to localized androgen-receptor degradation Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market-en/figure-04.png AnHorn AIMCADD and protein-degradation clinical-asset flywheel Investors, Take Note: Hair Loss Could Be Biotech's Next Weight-Loss-Drug-Sized Blockbuster https://drugnews.com.tw/articles/2026-08-06-anhorn-ah001-hair-loss-blockbuster-market.html https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/cover.png 掉髮新藥市場、毛囊與 AH-001 外用雄激素受體降解機制的商業分析封面投資人請注意，下一個減肥藥級別賽道來了！ https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-01.png Veradermics Study 302 的毛髮計數與患者自評結果圖投資人請注意，下一個減肥藥級別賽道來了！ https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-02.png 全球掉髮新藥競爭地圖與主要治療機制投資人請注意，下一個減肥藥級別賽道來了！ https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-03.png 從刺激毛囊到局部降解雄激素受體的治療機制演進投資人請注意，下一個減肥藥級別賽道來了！ https://drugnews.com.tw/assets/articles/anhorn-ah001-hair-loss-blockbuster-market/figure-04.png 安宏 AIMCADD 與蛋白質降解平台的臨床資產飛輪投資人請注意，下一個減肥藥級別賽道來了！ https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset-en.html https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/cover.png Amvuttra crossed one billion dollars in quarterly sales while Alnylam's growth expectations were reset More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%? https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-01.png Figure 1 More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%? https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-02.png Figure 2 More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%? https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-03.png Figure 3 More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%? https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset-en/figure-04.png Figure 4 More Than $1 Billion in One Quarter: Why Did Alnylam Plunge 28%? https://drugnews.com.tw/articles/2026-08-05-alnylam-amvuttra-ttr-growth-reset.html https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/cover.png Amvuttra 銷售突破 10 億美元，Alnylam 的成長預期卻被市場重新定價一季賣破 10 億，Alnylam 為何崩 28%？ https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-01.png Alnylam 與 Amvuttra 的營收成長與估值重估一季賣破 10 億，Alnylam 為何崩 28%？ https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-02.png Alnylam 2026 年第二季產品收入集中度一季賣破 10 億，Alnylam 為何崩 28%？ https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-03.png Amvuttra 上市後由積壓需求轉向常態需求的成長換檔一季賣破 10 億，Alnylam 為何崩 28%？ https://drugnews.com.tw/assets/articles/alnylam-amvuttra-ttr-growth-reset/figure-04.png Amvuttra、eplontersen 與 nucresiran 的臨床定位比較一季賣破 10 億，Alnylam 為何崩 28%？ https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks-en.html https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/cover.png Two pharmaceutical research ecosystems remain separated while reported AstraZeneca and BMS merger discussions are examined A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/homepage-cover.png Two pharmaceutical research ecosystems remain separated, reflecting reported AstraZeneca and BMS discussions without an announced transaction A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/figure-01-en.png AstraZeneca and BMS had a combined market value approaching $400 billion, but public evidence supports only reported exploratory discussions A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/figure-02-en.png The growth and patent-cliff logic that could bring AstraZeneca and BMS to the same negotiating table A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/figure-03-en.png Complementarity and overlap across solid tumors, immunotherapy, hematology and CAR-T in the AstraZeneca and BMS portfolios A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks-en/figure-04-en.png A reported AstraZeneca-BMS combination would still have to pass four gates: structure, governance, antitrust and pipeline integration A $400 Billion Pharma Merger? AstraZeneca and Bristol Myers Squibb Are Reportedly Talking https://drugnews.com.tw/articles/2026-08-04-astrazeneca-bms-400b-merger-talks.html https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/cover.png 阿斯特捷利康與 BMS 兩個製藥體系隔著尚未跨越的距離，對應報導中的 4,000 億美元合併可能性超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/homepage-cover.png 兩個製藥研發生態系隔著尚未跨越的距離，對應阿斯特捷利康與 BMS 合併傳聞尚未成案超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-01.png 阿斯特捷利康與 BMS 合計市值接近 4,000 億美元，但公開資訊仍只支持曾探討結合超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-02.png 阿斯特捷利康與 BMS 坐上同一張桌的成長與專利懸崖邏輯超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-03.png 阿斯特捷利康與 BMS 在實體瘤、免疫治療、血液腫瘤與 CAR-T 的互補及重疊超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/assets/articles/astrazeneca-bms-400b-merger-talks/figure-04.png 阿斯特捷利康與 BMS 的合併傳聞仍須跨過交易、治理、反壟斷與管線整合四道關超級大藥廠 4,000 億美元合併？阿斯特捷利康＋BMS！ https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3-en.html https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/cover.png Diranersen has given tau lowering a reason to advance into confirmatory testing Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/figure-01.png CELIA tested whether higher or more frequent dosing produced greater CDR-SB benefit Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/figure-02.png The lowest dose showed the largest CDR-SB difference, while the prespecified dose-response endpoint was missed Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/figure-03.png Mechanism, biomarkers and a selected clinical signal moved in the same direction but do not establish Phase 3 benefit Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3-en/figure-04.png Five questions a confirmatory diranersen trial must answer Tau Earned a Retest: Why Biogen Is Taking Diranersen Into Phase 3 After CELIA Missed Its Primary Endpoint https://drugnews.com.tw/articles/2026-08-03-diranersen-celia-tau-phase3.html https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/cover.png Diranersen 讓 Tau 降低策略取得進入第三期驗證的理由 Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？ https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/figure-01.png CELIA 的主要終點檢驗更高或更頻繁劑量是否帶來更大 CDR-SB 效益 Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？ https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/figure-02.png 最低劑量組在 CDR-SB 表現最好，但預設劑量反應主要終點仍未達 Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？ https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/figure-03.png 機制、生物標記與部分臨床結果同方向，仍不等於三期已證明患者效益 Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？ https://drugnews.com.tw/assets/articles/diranersen-celia-tau-phase3/figure-04.png Diranersen 第三期必須回答訊號重現、認知與功能、劑量窗、安全性及治療背景五個問題 Tau 拿到補考資格：Diranersen 主終點失敗，為什麼 Biogen 仍要進三期？ https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata-en.html https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/cover.png The follicular immune mechanism bempikibart must validate in larger clinical trials Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-01.png A 33-patient trial nearly doubled Q32 Bio shares, but the evidence remains an early Phase 2a signal Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-02.png The same 10 responders yield different percentages when the denominator changes from 25 to 33 Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-03.png A clean 33-patient safety signal cannot exclude low-frequency risks that emerge with larger exposure Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata-en/figure-04.png The next bempikibart test is Week 52 durability, controlled replication and larger safety exposure Bempikibart in Alopecia Areata: A 33-Patient Signal Is Not Yet a Win Over JAK Inhibitors https://drugnews.com.tw/articles/2026-08-02-bempikibart-alopecia-areata.html https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/cover.png Bempikibart 進入更大規模臨床驗證前的毛囊免疫機轉鬼剃頭新藥，先別封神 https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-01.png 33 人讓股價近乎翻倍，但單臂 Phase 2a 資料仍只是進入下一階段的門票鬼剃頭新藥，先別封神 https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-02.png 同樣 10 名患者達到 SALT 不超過 20，mITT 與 ITT 分母會得出不同百分比鬼剃頭新藥，先別封神 https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-03.png 33 人研究沒有觀察到嚴重安全事件，不代表擴大暴露後不會出現低頻重要風險鬼剃頭新藥，先別封神 https://drugnews.com.tw/assets/articles/bempikibart-alopecia-areata/figure-04.png Bempikibart 下一場考試包括第 52 週、對照設計、療效重現與長期安全鬼剃頭新藥，先別封神 https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink-en.html https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/cover.png A satellite constellation relays a therapeutic signal into a cold tumor as immune cells begin to infiltrate AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-01.png Figure 1 | A “Starlink” for cancer immunotherapy: ABT-301 is designed to carry immune signaling into tumors that remain beyond the reach of current treatment. AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-02.png Figure 2 | ABT-301 is designed to reprogram the tumor microenvironment—making the tumor visible again and reactivating an immune response. AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-03.png Figure 3 | A sequential network of the ABT-301 triple therapy: reprogram the microenvironment, improve immune access, and release the immune brake. AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-04.png Figure 4 | From one satellite to a full constellation: ABT-301’s expansion blueprint across drugs, tumor types, and partners. AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink-en/figure-05.png Figure 5 | AnBogen’s capital-markets trajectory: from the first signal in 66 patients to a cross-tumor platform and a globally partnerable asset. AnBogen Therapeutics: Building a “Starlink” for Cancer Immunotherapy https://drugnews.com.tw/articles/2026-07-31-anbogen-immunotherapy-starlink.html https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/cover.png 安邦生技 ABT-301 如衛星中繼訊號般把免疫治療送入目前難以覆蓋的冷腫瘤安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-01.png 圖1｜免疫治療的「星鏈計畫」：ABT-301嘗試把免疫訊號送進治療盲區安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-02.png 圖2｜ABT-301透過腫瘤微環境重塑，嘗試讓腫瘤重新被看見、讓免疫重新被啟動安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-03.png 圖3｜三聯療法的順序式邏輯：重塑環境、打開通道、解除煞車安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-04.png 圖4｜從一顆衛星到整個星座：ABT-301的跨藥物、跨癌種、跨夥伴擴張藍圖安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/assets/articles/anbogen-immunotherapy-starlink/figure-05.png 圖5｜安邦的資本市場想像：從66名患者的第一組訊號，走向跨癌種平台與全球合作資產安邦生技：免疫治療的「星鏈計畫」 https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html https://drugnews.com.tw/assets/articles/astellas-oncology-platform/cover.png 由單一藥物核心延伸至多條腫瘤研發路徑的抽象科學視覺 Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門 https://drugnews.com.tw/assets/articles/astellas-oncology-platform/01_%E4%B8%8D%E6%98%AF%E5%8F%AA%E6%9C%89Xtandi_%E4%BB%8D%E9%AB%98%E5%BA%A6%E9%9B%86%E4%B8%AD.png 安斯泰來不再只有 Xtandi，但產品組合仍高度集中 Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門 https://drugnews.com.tw/assets/articles/astellas-oncology-platform/02_Padcev%E8%B5%B0%E9%80%B2%E6%89%8B%E8%A1%93%E5%89%8D%E5%BE%8C.png Padcev 從晚期治療走進膀胱癌手術前後 Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門 https://drugnews.com.tw/assets/articles/astellas-oncology-platform/03_%E5%B9%B3%E5%8F%B0%E9%9B%9B%E5%BD%A2_%E5%9B%9B%E5%B8%82%E5%A0%B4%E4%B8%89%E6%A8%A1%E6%85%8B.png 安斯泰來已形成跨癌種、跨模態的平台雛形 Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門 https://drugnews.com.tw/assets/articles/astellas-oncology-platform/04_%E5%9B%9B%E9%81%93%E9%A9%97%E8%AD%89%E9%96%80.png 評估安斯泰來腫瘤平台的四道驗證門 Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門 https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform-en.html https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/cover-en.png An abstract scientific image of one medicine core branching into multiple oncology development paths After Xtandi: Can Astellas Build an Oncology Platform? https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-01-en.svg Astellas is no longer only Xtandi, but its oncology portfolio remains concentrated After Xtandi: Can Astellas Build an Oncology Platform? https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-02-en.svg Padcev moves from advanced disease into treatment before and after bladder-cancer surgery After Xtandi: Can Astellas Build an Oncology Platform? https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-03-en.svg Astellas has assembled the outline of a multi-tumor, multi-modality platform After Xtandi: Can Astellas Build an Oncology Platform? https://drugnews.com.tw/assets/articles/astellas-oncology-platform-en/figure-04-en.svg Four validation gates for Astellas’ emerging oncology platform After Xtandi: Can Astellas Build an Oncology Platform? https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon-en.html https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/homepage-cover.png An Lp(a) particle, unresolved question mark and heart visualize the unanswered HORIZON outcomes question Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events? https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-01.webp HORIZON must establish whether lowering Lp(a) reduces cardiovascular events, not merely whether the biomarker falls Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events? https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-02.webp Pelacarsen reduces apo(a) production and Lp(a), while the connection to fewer cardiovascular events remains to be proven Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events? https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-03.webp A five-layer framework for reading HORIZON: hypothesis, effect size, endpoint composition, biomarker linkage and long-term burden Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events? https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon-en/figure-04.webp Four checks for Taiwan readers: population, measurement units, local access and direct investment evidence Pelacarsen's HORIZON Test: Does Lowering Lp(a) Prevent Cardiovascular Events? https://drugnews.com.tw/articles/2026-07-19-pelacarsen-lpa-horizon.html https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/cover.png Lp(a) 粒子、心血管事件與問號橋樑構成 HORIZON 臨床結果尚待驗證的科學主視覺 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/homepage-cover.png Lp(a) 粒子、未解問號與心臟構成 HORIZON 臨床結果待驗證的首頁主視覺 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-01.webp HORIZON 真正要驗證的是降低 Lp(a) 能否減少心血管事件，而非只看生物標記下降 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-02.webp Pelacarsen 從肝臟 LPA mRNA、apo(a) 生成到 Lp(a) 下降的作用鏈，臨床事件端仍待 HORIZON 驗證 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-03.webp HORIZON 結果應從預設檢定、效果量、事件組成、降幅連結與長期代價五層判讀 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/assets/articles/pelacarsen-lpa-horizon/facebook-04.webp 台灣讀者判讀 HORIZON 的四個檢查點：族群、單位、臨床落地與直接證據 HORIZON：Lp(a) 降了，心梗會少嗎？ https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability-en.html https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability-en/cover-en.webp PD-1 blockade, CAR-T and T-cell engagers all depend on durable T-cell fitness T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability-en/01_three-modalities-en.webp PD-1 blockade, CAR-T and T-cell engagers all depend on T cells that can expand, renew and persist T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability-en/02_exhaustion-trajectory-en.webp T-cell exhaustion progresses from progenitor-like through transitional to terminal states under persistent antigen and microenvironmental pressure T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability-en/03_product-engineering-en.webp CAR-T and T-cell engagers must balance tumor killing, toxicity and T-cell persistence through product-specific engineering levers T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability-en/04_taiwan-coordinates-en.webp SOA101, CAR001, PL001 and AP203 represent four direct Taiwan product coordinates, with ACE1831 as an adjacent T-cell therapy comparison T-cell Exhaustion Across PD-1, CAR-T and TCE: Immunotherapy's Next Contest Is Durability https://drugnews.com.tw/articles/2026-07-28-t-cell-exhaustion-immunotherapy-durability.html https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability/cover-zh.webp PD-1、CAR-T 與 TCE 都依賴可長期維持的 T 細胞戰力 T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability/01_three-modalities.webp PD-1 阻斷、CAR-T 與 TCE 都依賴可增殖、可補充且能持久的 T 細胞戰力 T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability/02_exhaustion-trajectory.webp T 細胞耗竭從前驅樣、過渡到終末耗竭，是受到持續抗原與微環境壓力塑造的分化路徑 T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability/03_product-engineering.webp CAR-T 與 TCE 都必須在腫瘤殺傷、毒性與 T 細胞持久性之間找到產品自己的治療窗 T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/assets/articles/t-cell-exhaustion-immunotherapy-durability/04_taiwan-coordinates.webp 聖安生醫 SOA101、長聖 CAR001、沛爾生醫 PL001 與圓祥 AP203 是台灣四個直接產品座標，育世博 ACE1831 為延伸觀察 T 細胞耗竭卡住 PD-1、CAR-T 與 TCE：免疫治療下半場，拼的是誰能撐到最後 https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time.html https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/cover-zh.webp 大型藥廠在專利懸崖前透過併購買進臨床時間半年千億，買的是時間 https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/01_%E5%85%A9%E5%80%8B%E7%B5%B1%E8%A8%88%E4%B8%8D%E8%83%BD%E7%A1%AC%E6%8B%BC.webp BioSpace 與 IQVIA 的統計口徑不同，52 筆與 42 筆不能直接相加半年千億，買的是時間 https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/02_%E5%B0%88%E5%88%A9%E6%87%B8%E5%B4%96%E8%B2%B7%E6%99%82%E9%96%93.webp 專利懸崖迫使大型藥廠以更高價格購買接近讀出、申請或上市的時間半年千億，買的是時間 https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/03_%E5%85%AD%E7%AD%86%E4%BA%A4%E6%98%93%E7%8B%80%E6%85%8B.webp 六筆代表交易分別處於宣布、完成、早期臨床、FDA 審查與等待交割等不同狀態半年千億，買的是時間 https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time/04_%E4%BA%A4%E6%98%93%E6%A2%9D%E6%AC%BE%E5%88%86%E9%85%8D%E9%A2%A8%E9%9A%AA.webp 前期現金、里程碑、CVR 與交割條件把併購風險分配給不同參與者半年千億，買的是時間 https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/cover-en.webp Big Pharma buys measurable clinical time before the patent cliff $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/01-dataset-methodology.webp BioSpace and IQVIA use different inclusion rules, so 52 transactions and 42 transactions cannot be combined $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/02-buying-time-before-patent-cliff.webp Patent cliffs increase the value of assets that are closer to readout, filing, review or launch $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/03-six-deals-six-states.webp Six representative transactions occupy different states, from announcement and closing to early clinical development and FDA review $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/04-how-deal-terms-allocate-risk.webp Upfront cash, milestones, CVRs and closing conditions allocate different parts of transaction risk $130 Billion in Six Months: Big Pharma Is Buying Time https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine-en.html https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/cover-en.webp Roche uses established clinical, diagnostic, and commercial capabilities to carry new molecules into its next growth cycle Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-01-en.webp Roche's established products hand clinical and commercial infrastructure to the next generation of medicines Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-02-en.webp Roche's near-term filings, mid-term phase 3 programs, and longer-term options form a three-layer succession map Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-04-en.webp Roche reuses clinical trials, diagnostics, physician networks, and commercial channels across six disease areas Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine-en/figure-03-en.webp BRIM Biotechnology's four ophthalmology assets face a prove, license, and scale succession test Roche's Hidden Succession Engine: How 19 New Molecules Could Power the Next Growth Cycle https://drugnews.com.tw/articles/2026-07-25-roche-19-molecule-succession-engine.html https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/cover-zh.webp 羅氏以既有臨床、診斷與商業能力把新分子接進下一個成長週期羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？ https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-01-zh.webp 羅氏成熟產品把臨床試驗與商業通路交給下一代藥物羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？ https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-02-zh.webp 羅氏以近端申報、中段三期與遠端新選擇權構成三層接棒架構羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？ https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-04-zh.webp 羅氏把臨床試驗、診斷、醫師網路與商業通路重複用在六個疾病版圖羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？ https://drugnews.com.tw/assets/articles/roche-19-molecule-succession-engine/figure-03-zh.webp 全福生技四項眼科資產從證明、授權到放大的接棒考題羅氏的隱藏底牌：19 個新分子排隊接棒，下一個成長週期怎麼長出來？ https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals-en.html https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals-en/cover-en.webp A SpaceX launch sends crystallization research to orbit before samples return to Earth for analysis SpaceX Goes to Orbit. Is the Money in the Crystals? https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals-en/figure-01-en.webp Candidate molecules travel to orbit and crystal samples return to Earth for analysis SpaceX Goes to Orbit. Is the Money in the Crystals? https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals-en/figure-02-en.webp Crystal growth under gravity compared with the potential effects of microgravity SpaceX Goes to Orbit. Is the Money in the Crystals? https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals-en/figure-03-en.webp Minimum viable value chain for space-enabled pharmaceutical research and manufacturing SpaceX Goes to Orbit. Is the Money in the Crystals? https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals-en/figure-04-en.webp Taiwan capability map from mission integration and launch-return logistics to planned X-ray crystallography SpaceX Goes to Orbit. Is the Money in the Crystals? https://drugnews.com.tw/articles/2026-07-24-spacex-microgravity-drug-crystals.html https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals/cover-zh.webp SpaceX 火箭把結晶實驗送上軌道，再將樣本帶回地球分析 SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金 https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals/01_SpaceX_%E6%8A%8A%E8%97%A5%E9%80%81%E4%B8%8A%E5%A4%AA%E7%A9%BA_GPT.webp SpaceX 把候選分子送上太空，再把晶體樣本帶回地球 SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金 https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals/02_%E5%9C%B0%E7%90%83%E8%88%87%E5%BE%AE%E9%87%8D%E5%8A%9B%E6%99%B6%E9%AB%94_GPT.webp 地球重力與微重力下的晶體生長差異 SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金 https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals/03_%E5%A4%AA%E7%A9%BA%E8%A3%BD%E8%97%A5%E5%83%B9%E5%80%BC%E9%8F%88_GPT.webp 太空製藥的最小可行價值鏈 SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金 https://drugnews.com.tw/assets/articles/spacex-microgravity-drug-crystals/04_%E5%8F%B0%E7%81%A3%E5%A4%AA%E7%A9%BA%E7%B5%90%E6%99%B6%E5%BA%A7%E6%A8%99_GPT.webp 台灣太空結晶能力座標 SpaceX 上太空，錢在晶體裡？微重力製藥的第一桶金 https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines-en.html https://drugnews.com.tw/assets/articles/biotech-independence-five-engines-en/cover-en.png A molecular platform bridging discovery, clinical development, manufacturing, commercialization, and durable financing When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines-en/figure-01-en.png Five engines of biotech independence When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines-en/figure-03-en.png Revolution Medicines' financing, retained control, and 15-year cost When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines-en/figure-02-en.png Four companies at four stages of independence When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines-en/figure-04-en.png Five questions for biotech independence When a Biotech Says No to a Sale: Five Tests of Whether It Can Become a Biopharma https://drugnews.com.tw/articles/2026-07-24-biotech-independence-five-engines.html https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/cover.png 一個分子核心向產品證據、現金、第二曲線、全球執行與融資能力延伸的科學視覺 Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/01_%E4%B8%8D%E8%B3%A3%E8%B3%87%E6%A0%BC%E4%BA%94%E5%BC%95%E6%93%8E.png Biotech 的不賣資格：五個引擎 Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/03_Revolution%E7%8D%A8%E7%AB%8B%E5%AE%9A%E9%87%91.png Revolution 的獨立定金：資金、控制權與成本 Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/02_%E5%9B%9B%E5%85%AC%E5%8F%B8%E5%9B%9B%E9%9A%8E%E6%AE%B5.png 四家公司，四個獨立階段 Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma https://drugnews.com.tw/assets/articles/biotech-independence-five-engines/04_%E4%B8%8D%E8%B3%A3%E8%B3%87%E6%A0%BC%E4%BA%94%E5%95%8F.png Biotech 有沒有不賣資格：五個問題 Biotech 不賣，憑什麼？五張門票決定它能否長成 Biopharma https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform-en.html https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/cover.png A liver, Rezdiffra and precision gene-silencing signals visualize Madrigal's MASH cornerstone-drug and siRNA platform strategy Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/homepage-cover.png Madrigal expands from Rezdiffra as a MASH cornerstone into a precision siRNA combination matrix Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-01.webp Rezdiffra is evolving from FDA accelerated approval into a MASH cornerstone while confirmatory studies continue Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-02.webp The MASH treatment matrix combines four complementary mechanisms: Rezdiffra, GLP-1, FGF21 and siRNA Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-03.webp Madrigal is pursuing a dual-track siRNA strategy through Ribo's six early-stage programs and Arrowhead's clinical-stage ARO-PNPLA3 Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform-en/figure-04.webp Rezdiffra's clinical, diagnostic, payer and prescribing networks can amplify the commercialization of future MASH combination programs Madrigal's MASH Platform Strategy: Rezdiffra as the Cornerstone, siRNA as the Next Growth Engine https://drugnews.com.tw/articles/2026-07-20-madrigal-mash-sirna-platform.html https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/cover.png 肝臟、Rezdiffra 與精準基因沉默訊號構成 Madrigal MASH 基石藥與 siRNA 平台策略主視覺聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/homepage-cover.png Madrigal 以 Rezdiffra 為基石、向 siRNA 精準聯用矩陣擴張的 MASH 首頁主視覺聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-01.webp Rezdiffra 從 FDA 加速核准走向 MASH 基石藥；確認性研究仍在進行聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-02.webp MASH 治療矩陣由 Rezdiffra、GLP-1、FGF21 與 siRNA 四種互補機制構成聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-03.webp Madrigal 以 Ribo 六條早期 siRNA 管線與 Arrowhead 臨床階段 ARO-PNPLA3 建立雙軌策略聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/assets/articles/madrigal-mash-sirna-platform/figure-04.webp Rezdiffra 的臨床、診斷、給付與處方網絡，成為後續 MASH 聯用管線的商業放大器聯手巨頭卡位 MASH：Madrigal 把 Rezdiffra 做成基石藥，小核酸開始接棒 https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift-en.html https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/cover.png Editorial illustration of organoids, organ-on-a-chip technology and computational evidence in a regulatory workflow Animal Studies Are Not Disappearing. Drug Development Rules Are Changing. https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/figure-01.webp Three human-relevant evidence platforms: organoids, organ-on-a-chip technology and computational models Animal Studies Are Not Disappearing. Drug Development Rules Are Changing. https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/figure-02.webp CDE PIONEER's two entry points for drug developers and method developers Animal Studies Are Not Disappearing. Drug Development Rules Are Changing. https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/figure-03.webp FDA, EMA and MHRA illustrate different pathways toward regulatory acceptance of NAMs Animal Studies Are Not Disappearing. Drug Development Rules Are Changing. https://drugnews.com.tw/assets/articles/nams-regulatory-shift-en/figure-04.webp Where NAMs can create value: organoids, CGT, AI validation and integrated CRO services Animal Studies Are Not Disappearing. Drug Development Rules Are Changing. https://drugnews.com.tw/articles/2026-07-19-nams-regulatory-shift.html https://drugnews.com.tw/assets/articles/nams-regulatory-shift/cover.png 類器官、器官晶片與資料網路組成的新方法學藥物研發視覺動物實驗不是消失，而是藥物研發規則開始換代 https://drugnews.com.tw/assets/articles/nams-regulatory-shift/01_NAMs_%E8%97%A5%E7%89%A9%E7%A0%94%E7%99%BC%E4%B8%8D%E5%86%8D%E5%8F%AA%E9%9D%A0%E5%8B%95%E7%89%A9%E5%AF%A6%E9%A9%97.jpg 類器官、器官晶片與新方法學共同組成更接近人體的證據鏈動物實驗不是消失，而是藥物研發規則開始換代 https://drugnews.com.tw/assets/articles/nams-regulatory-shift/02_CDE%E5%85%88%E9%8B%92%E8%A8%88%E7%95%AB_%E5%85%A9%E5%80%8B%E5%85%A5%E5%8F%A3%E5%85%AB%E5%80%8B%E5%A0%B4%E6%99%AF.jpg CDE 先鋒計畫為藥企與方法開發者設計兩個入口及多個應用場景動物實驗不是消失，而是藥物研發規則開始換代 https://drugnews.com.tw/assets/articles/nams-regulatory-shift/03_%E5%85%A8%E7%90%83NAMs%E7%9B%A3%E7%AE%A1%E7%AB%B6%E8%B3%BD.jpg FDA、EMA、MHRA 與 CDE 的 NAMs 監管路徑各有不同節奏動物實驗不是消失，而是藥物研發規則開始換代 https://drugnews.com.tw/assets/articles/nams-regulatory-shift/figure-04.jpg 類器官、器官晶片、CGT、AI 製藥與 CRO 的產業價值鏈可能被重新定價動物實驗不是消失，而是藥物研發規則開始換代 https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200-en.html https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/cover.png An antibody-drug conjugate carrying glucocorticoid payloads approaches a VISTA-positive immune cell When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/cover-1400.webp An antibody-drug conjugate delivers an immune-modulating payload toward an autoimmune disease-relevant cell When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-01.webp The ADC platform moves from selective tumor killing toward selective immune modulation in autoimmune disease When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-02.webp Autoimmune ADCs follow two development paths: cell depletion and cell-selective immune modulation When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-03.webp LFD-200 targets VISTA-positive immune cells with eight glucocorticoid payloads and has produced an early human proof-of-mechanism signal When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200-en/figure-04.webp Autoimmune ADCs may occupy the strategic space between conventional biologics, small molecules and operationally intensive cell therapy When ADCs Enter Autoimmune Disease: Precision Immune Modulation, Not More Killing https://drugnews.com.tw/articles/2026-07-18-autoimmune-adc-lfd200.html https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/cover.png 一組定向遞送 glucocorticoid payload 的抗體藥物複合體靠近 VISTA 陽性免疫細胞當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/cover-1400.webp 抗體藥物複合體將免疫調節 payload 定向送往自體免疫疾病相關細胞當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-01.webp ADC 從腫瘤的選擇性殺傷，延伸到自體免疫疾病的選擇性免疫調節當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-02.webp 自體免疫 ADC 分成細胞清除與免疫調節兩條技術路線當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-03.webp LFD-200 將八個 glucocorticoid payload 定向送入 VISTA 陽性免疫細胞的作用機制與早期人體訊號當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/assets/articles/autoimmune-adc-lfd200/figure-04.webp 自體免疫 ADC 位於傳統生物製劑、小分子與重型細胞治療之間的商業定位當 ADC 走進自體免疫：不是殺得更狠，而是調得更準 https://drugnews.com.tw/articles/2026-07-17-revmed-ras.html https://drugnews.com.tw/assets/articles/revmed-ras/cover.png KRAS 分子開關與雙重 RAS 阻斷共同切斷胰臟癌逃脫路徑的科學主視覺又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代 https://drugnews.com.tw/assets/articles/revmed-ras/facebook-01.webp 胰臟癌中的 KRAS G12D 分子開關與下游訊號路徑又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代 https://drugnews.com.tw/assets/articles/revmed-ras/facebook-02.webp Zoldonrasib 與 daraxonrasib 從突變深度與逃脫路徑廣度形成 RAS 雙封鎖又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代 https://drugnews.com.tw/assets/articles/revmed-ras/facebook-03.webp ESMO GI 2026 公布的 zoldonrasib 與 daraxonrasib 組合療法早期臨床訊號又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代 https://drugnews.com.tw/assets/articles/revmed-ras/facebook-04.webp RevMed 以 daraxonrasib 為骨架建立多突變、多治療線與多組合的 RAS 產品矩陣又一次RevMed 直接掀桌，胰臟癌進入 RAS 組合療法時代 https://drugnews.com.tw/articles/2026-07-17-revmed-ras-en.html https://drugnews.com.tw/assets/articles/revmed-ras-en/cover.png A molecular RAS switch in pancreatic cancer is blocked by complementary selective and broad-spectrum inhibitors RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-01.webp Why pancreatic cancer is difficult: KRAS G12D functions as a central driver of RAS signaling RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-02.webp Zoldonrasib provides mutation-specific depth while daraxonrasib broadens blockade across RAS escape routes RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-03.webp Early zoldonrasib combination cohorts reported notable response and disease-control signals, with longer follow-up still required RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived https://drugnews.com.tw/assets/articles/revmed-ras-en/figure-04.webp RevMed is organizing daraxonrasib and mutation-selective agents into a multi-line RAS combination franchise RevMed Upends Pancreatic Cancer Again: The RAS Combination Era Has Arrived https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic-en.html https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/cover.png A precision scientific gateway selecting differentiated biotech assets for Big Pharma Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/figure-01.webp The new $10 billion M&A wave, led by Vertex-Crinetics, Sun Pharma-Organon and Lilly-Centessa Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/figure-02.webp Big-market acquisitions now demand a technological step-change in immunology, RNA delivery or antiviral prevention Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/figure-03.webp Three shifts in Big Pharma acquisition taste: scale, fashionable platforms and differentiated certainty Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic-en/figure-04.webp Taiwan biotech examples that translate specialist leadership, formulation innovation and unmet need into strategic value Big Pharma's New $10 Billion M&A Wave: Why Differentiation Now Beats Scale and Hype https://drugnews.com.tw/articles/2026-07-16-big-pharma-ma-new-aesthetic.html https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/cover.png 大型藥廠從眾多生技資產中精準篩選差異化標的的科學商業主視覺百億美元併購新狂潮 https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-01.webp 2026 年大型藥廠百億美元級併購，從規模競賽轉向細分市場與專科領導力百億美元併購新狂潮 https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-02.webp 留在免疫、神經肌肉與感染等大賽道的藥廠，改以長效抗體、AOC 與 DFC 取得代際差異百億美元併購新狂潮 https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-03.webp Big Pharma 併購審美從規模崇拜、風口崇拜，走向差異化與確定性百億美元併購新狂潮 https://drugnews.com.tw/assets/articles/big-pharma-ma-new-aesthetic/facebook-04.webp 藥華藥、逸達與昱展新藥分別以專科市場、長效製劑與明確臨床需求建立差異化百億美元併購新狂潮 https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization-en.html https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/cover.png A regulatory T cell suppressing excessive immune activation while a controlled cell-manufacturing workflow supports transplant tolerance After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/figure-01.webp Regulatory T cells suppress excessive immune activation and help restore immune tolerance After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/figure-02.webp Productization requires Treg identity, potency, manufacturing consistency, clinical evidence and a workable commercial model After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/figure-03.webp In vivo Treg expansion, ex vivo Treg therapy and engineered Treg solve different product problems and carry different development tests After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization-en/figure-04.webp Taiwan Bio Therapeutics' TRK-001 should be followed through cell identity and potency, manufacturing consistency, clinical endpoints and access After the Nobel Prize, Do Not Rush the First-Approved Treg Story: The Real Test Is Turning Immune Tolerance Into a Product https://drugnews.com.tw/articles/2026-07-15-treg-immune-tolerance-productization.html https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/cover.png 調節性 T 細胞抑制過度免疫反應並串連細胞製造與移植耐受的科學主視覺諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品 https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-01.webp Treg 科學從免疫耐受概念走向可製造、可追蹤與可交付的細胞產品諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品 https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-02.webp 調節性 T 細胞像免疫系統的煞車，在必要時抑制過度反應並維持周邊免疫耐受諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品 https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-03.webp Treg 產品化可分為體內誘導或擴增、體外細胞療法與工程化 Treg 三條路徑諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品 https://drugnews.com.tw/assets/articles/treg-immune-tolerance-productization/facebook-04.webp 台寶 TRK-001 自體 Treg 從採血、體外擴增、腎移植後回輸到第二期試驗的產品化路徑諾貝爾獎後，Treg 第一個獲批藥還不能急著喊：真正的考題是免疫耐受怎麼做成產品 https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc-en.html https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/cover.png A next-generation antibody-drug conjugate entering a tumor cell and delivering a novel payload toward intracellular trafficking machinery The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/figure-01.webp A next-generation ADC must integrate target choice, linker performance, payload differentiation, therapeutic window, resistance and platform scalability The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/figure-02.webp An NMTi-ADC binds a tumor antigen, enters the cell, releases its payload and disrupts intracellular protein trafficking and survival programs The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/figure-03.webp The Novartis-Myricx transaction combines two lead ADC assets, an NMTi payload platform and broader oncology option value The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc-en/figure-04.webp Taiwan's ADC watchlist should distinguish verified pipelines, technology moving toward the clinic and companies that still need greater public-data transparency The Next ADC War: Novartis Is Paying Up to $1.5 Billion for Myricx, but the Real Prize Is a New Payload Class https://drugnews.com.tw/articles/2026-07-14-novartis-myricx-nmti-adc.html https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/cover.png 新型 NMTi payload 抗體藥物複合體進入腫瘤細胞並干擾細胞內機制的科學主視覺 ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-01.webp ADC 下一場競爭將從熱門靶點推進到 payload、安全窗、耐藥與平台可複製性的綜合比較 ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-02.webp 下一代 ADC 必須同時回答靶點、linker、payload、安全窗、耐藥與平台延伸能力 ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-03.webp NMTi-ADC 透過抗體將新型 payload 送入腫瘤細胞並干擾關鍵細胞功能依賴 ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload https://drugnews.com.tw/assets/articles/novartis-myricx-nmti-adc/facebook-04.webp 台灣 ADC 公司要分別從公開管線、技術進臨床與資料透明度三條證據線觀察 ADC 下一場戰爭：諾華 15 億美元買 Myricx，真正搶的是新型 payload https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery-en.html https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/cover.png Scientific visualization connecting AI models, molecular design, wet-lab experiments and clinical readouts in a drug discovery loop Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/figure-01.webp Claude Science connects literature, models, compute, wet-lab work and validation in a repeatable experimental feedback loop Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/figure-02.webp AI drug discovery creates three distinct layers of value through research workflows, R&D partnerships and tradable assets Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/figure-03.webp A model output must pass through experimental validation, development gates and human evidence before it becomes a drug asset Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery-en/figure-04.webp Anthropic and AnHorn Medicines enter the same AI drug discovery landscape from scientific workflows and AI-native asset creation Foundation Models Enter Drug Discovery: Anthropic Launches Claude Science as AI Companies Move Into the Real R&D Arena https://drugnews.com.tw/articles/2026-07-13-anthropic-claude-science-ai-drug-discovery.html https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/cover.png AI 模型、分子設計、濕實驗與臨床資料串成藥物研發閉環的科學主視覺大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場 https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/facebook-01.jpg Claude Science 把文獻、模型、運算、濕實驗與驗證串成可反覆學習的研發閉環大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場 https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/facebook-02-v2.jpg AI 製藥從科研工作流、研發合作走向可交易資產的三層估值邏輯大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場 https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/facebook-03.jpg 大模型必須把模型輸出接到實驗、臨床與可交易資產，才真正進入藥物研發大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場 https://drugnews.com.tw/assets/articles/anthropic-claude-science-ai-drug-discovery/facebook-04.jpg Anthropic 與安宏生醫分別從科研工作台與 AI 原生新藥研發切入同一張產業地圖大模型公司走進 AI 製藥：Anthropic 推出 Claude Science，模型公司開始把藥物研發當成真實戰場 https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation-en.html https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/cover.png Premium scientific cover of divarasib binding the KRAS G12C Switch-II pocket Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/figure-01.webp KRAS G12C moves from proving druggability to generational head-to-head competition Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/figure-02.webp Divarasib development moves from later-line monotherapy into first-line combinations Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/figure-03.webp The RAS 2.0 landscape deepens G12C while broadening toward G12D, G12V and pan-RAS Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation-en/figure-04.webp How investors can read KRAS competition and Taiwan's role in precision oncology Winning First Is Not Winning: Roche's Divarasib Pushes KRAS Into a Generational Elimination Race https://drugnews.com.tw/articles/2026-07-12-roche-divarasib-kras-generation.html https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/cover.png divarasib 鎖定 KRAS G12C Switch-II 口袋的專業科學封面先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰 https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/facebook-01.jpg KRAS G12C 從 2021 年 FIC 速度戰進入 2026 年頭對頭三期世代淘汰先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰 https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/facebook-02.jpg divarasib 鎖定 KRAS G12C Switch-II 口袋並阻斷 RAF-MEK-ERK 訊號先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰 https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/facebook-03.jpg divarasib 從後線頭對頭試驗推進第一線與 pembrolizumab 聯用先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰 https://drugnews.com.tw/assets/articles/roche-divarasib-kras-generation/facebook-04.jpg 智擎、浩鼎與台灣臨床試驗能力在全球精準腫瘤開發網絡的角色先贏不是贏：Roche divarasib 把 KRAS 賽道推進世代淘汰戰 https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns.html https://drugnews.com.tw/assets/articles/fasedienol-cns/cover.png Fasedienol 鼻噴劑、CNS 神經迴路與臨床證據閘門的無文字科學封面社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格 https://drugnews.com.tw/assets/articles/fasedienol-cns/facebook-01.png Facebook 原圖：社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格（圖 1）社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格 https://drugnews.com.tw/assets/articles/fasedienol-cns/facebook-02.png Facebook 原圖：社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格（圖 2）社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格 https://drugnews.com.tw/assets/articles/fasedienol-cns/facebook-03.png Facebook 原圖：社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格（圖 3）社恐神藥三期踩煞車：Fasedienol 不是輸在故事，而是輸在 CNS 新藥最難證明的一格 https://drugnews.com.tw/articles/2026-07-11-fasedienol-cns-en.html https://drugnews.com.tw/assets/articles/fasedienol-cns-en/cover.png Text-free premium scientific cover showing fasedienol nasal spray, CNS neural circuitry, and an evidence gate Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/assets/articles/fasedienol-cns-en/figure-01.png PALISADE-4 Phase 3 primary endpoint result: fasedienol missed the SUDS endpoint versus placebo Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/assets/articles/fasedienol-cns-en/figure-02.png PALISADE-4 post-hoc severe subgroup signal and why it needs prospective confirmation Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/assets/articles/fasedienol-cns-en/figure-03.png Endpoint shift from SUDS acute distress to LSAS longitudinal disease burden Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/assets/articles/fasedienol-cns-en/figure-04.png CNS investor risk stack: clinical, statistical, and commercial risk after PALISADE-4 Fasedienol's Phase 3 Brake: The Story Did Not Fail. The CNS Evidence Bar Did Its Job. https://drugnews.com.tw/articles/2026-07-10-fda-nasp-en.html https://drugnews.com.tw/assets/articles/fda-nasp-en/cover.png Premium editorial cover showing NASP gout biology and a biologics manufacturing quality gate Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-01.png Figure 1 | NASP combines nanoencapsulated sirolimus with pegadricase to pair immune modulation with uric acid breakdown Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-02.png Figure 2 | The NASP CRL separated clinical performance from CMC and contract-manufacturing execution Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-03.png Figure 3 | NASP reached the final regulatory mile after Phase 3, but must now remediate CMC and facility issues before resubmission Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/assets/articles/fda-nasp-en/figure-04.png Figure 4 | Gout treatment spans high-end biologics, URAT1 uricosurics, and established chronic therapies Sobi's NASP Received an FDA CRL: The Problem Was Manufacturing Credibility, Not Efficacy https://drugnews.com.tw/articles/2026-07-10-fda-nasp.html https://drugnews.com.tw/assets/articles/fda-nasp/cover.png NASP 痛風新藥、尿酸結晶與生物製劑製造品質關卡的高階商業分析封面痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/assets/articles/fda-nasp/homepage-cover.webp NASP 痛風新藥、尿酸結晶與生物製劑製造品質關卡的首頁橫幅封面痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/assets/articles/fda-nasp/facebook-02.png NASP 以奈米包封 sirolimus 搭配 pegadricase，兼顧免疫調節與尿酸分解痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/assets/articles/fda-nasp/facebook-01.png NASP 的 FDA CRL 聚焦 CMC 與委託製造缺失，而非臨床療效或安全性痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/assets/articles/fda-nasp/facebook-03.png NASP 從第三期臨床、BLA 審查走到 FDA CRL 的開發路徑痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/assets/articles/fda-nasp/facebook-04.png 台灣高尿酸與痛風用藥鏈：URAT1、尿酸生成抑制與難治性高階療法痛風新藥被 FDA 打回票：NASP 沒輸在療效，而是卡在製造可信度 https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap-en.html https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/cover.png Premium editorial cover for Japan biotech ecosystem and global competitiveness gap Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-01.png Figure 1 | Japan's biotech paradox: strong science, major pharma, large market, but few global biotech startups Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-02.png Figure 2 | Large pharma can become the main container for innovation, leaving the startup learning curve thin Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-03.png Figure 3 | Startup scaling needs talent mobility and risk capital across clinical, CMC, regulatory, and BD execution Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap-en/figure-04.png Figure 4 | Taiwan investors should read ecosystem position rather than chasing biotech themes Why Has Japan Struggled to Build Global-Scale Biotech Companies? https://drugnews.com.tw/articles/2026-07-09-japan-biotech-ecosystem-global-gap.html https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/cover.png 日本 Biotech 產業生態與全球競爭力落差的高階商業分析封面日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態 https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/facebook-01.png Facebook 原圖：日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態（圖 1）日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態 https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/facebook-02.png Facebook 原圖：日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態（圖 2）日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態 https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/facebook-03.png Facebook 原圖：日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態（圖 3）日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態 https://drugnews.com.tw/assets/articles/japan-biotech-ecosystem-global-gap/facebook-04.png Facebook 原圖：日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態（圖 4）日本為什麼長不出全球級 Biotech？問題不在科學，而在產業生態 https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base-en.html https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/cover.png Premium editorial cover for GLP-1, dorzagliatin, and sustainable metabolic therapy GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-01.png Figure 1 | GLP-1's second half is about durability, tolerability, dose pressure, and rebound risk GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-02.png Figure 2 | Dorzagliatin is framed as a glucose-sensor reset through glucokinase biology GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-03.png Figure 3 | Dorzagliatin plus GLP-1 is a combination-design question, not a simple add-on slogan GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base-en/figure-04.png Figure 4 | Metabolic drug development is shifting toward mechanism combinations across MASH, T2D, lipids, and uric acid GLP-1's Second Half: Why Dorzagliatin Is About Making Metabolic Therapy Last https://drugnews.com.tw/articles/2026-07-08-glp1-dorzagliatin-long-term-metabolic-base.html https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/cover.png GLP-1、dorzagliatin 與長期代謝治療的高階生技商業分析封面 GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住 https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-01.png Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 1） GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住 https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-02.png Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 2） GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住 https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-03.png Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 3） GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住 https://drugnews.com.tw/assets/articles/glp1-dorzagliatin-long-term-metabolic-base/facebook-04.png Facebook 原圖：GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住（圖 4） GLP-1 下半場：dorzagliatin（多格列艾汀）想解決的，不是減重更猛，而是長期用得住 https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf-en.html https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/cover.png Premium editorial cover for Pfizer's ADC and PD-1/VEGF bispecific oncology strategy Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-01.png Pfizer oncology reset Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-02.png Why PD-1/VEGF matters Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-03.png Combination engine Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf-en/figure-04.png Taiwan investor lens Pfizer's ADC Bet: Why 3SBio's PD-1/VEGF Bispecific Has Become the New Pivot https://drugnews.com.tw/articles/2026-07-07-pfizer-seagen-3sbio-adc-pd1-vegf.html https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/cover.png 輝瑞 ADC 與 PD-1/VEGF 雙抗聯合療法策略專題封面【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】 https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-01.png Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 1）【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】 https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-02.png Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 2）【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】 https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-03.png Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 3）【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】 https://drugnews.com.tw/assets/articles/pfizer-seagen-3sbio-adc-pd1-vegf/facebook-04.png Facebook 原圖：【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】（圖 4）【輝瑞 ADC 賭局：430 億美元買下 Seagen 之後，為什麼 3SBio 的 PD-1/VEGF 雙抗變成新支點？】 https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound.html https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/cover.png 通用型 CAR-T 與細胞治療普及化的高級科學封面通用型 CAR-T 的 2026 從低谷回暖 https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-01.png Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 1）通用型 CAR-T 的 2026 從低谷回暖 https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-02.png Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 2）通用型 CAR-T 的 2026 從低谷回暖 https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-03.png Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 3）通用型 CAR-T 的 2026 從低谷回暖 https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound/facebook-04.png Facebook 原圖：通用型 CAR-T 的 2026 從低谷回暖（圖 4）通用型 CAR-T 的 2026 從低谷回暖 https://drugnews.com.tw/articles/2026-07-06-universal-car-t-2026-rebound-en.html https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/cover.png Premium editorial cover for the 2026 rebound of off-the-shelf allogeneic CAR-T therapies Off-the-Shelf CAR-T in 2026: Rebounding From the Trough https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-01.png Off-the-shelf CAR-T workflow Off-the-Shelf CAR-T in 2026: Rebounding From the Trough https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-02.png Vispa-cel clinical signal Off-the-Shelf CAR-T in 2026: Rebounding From the Trough https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-03.png Beyond last-line rescue Off-the-Shelf CAR-T in 2026: Rebounding From the Trough https://drugnews.com.tw/assets/articles/universal-car-t-2026-rebound-en/figure-04.png The next cell therapy race Off-the-Shelf CAR-T in 2026: Rebounding From the Trough https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma.html https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/cover.png 半年併購 1,340 億美元：Big Pharma 到底在搶什麼？專題封面半年併購 1,340 億美元：Big Pharma 到底在搶什麼？ https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-01.png Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 1）半年併購 1,340 億美元：Big Pharma 到底在搶什麼？ https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-02.png Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 2）半年併購 1,340 億美元：Big Pharma 到底在搶什麼？ https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-03.png Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 3）半年併購 1,340 億美元：Big Pharma 到底在搶什麼？ https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma/facebook-04.png Facebook 原圖：半年併購 1,340 億美元：Big Pharma 到底在搶什麼？（圖 4）半年併購 1,340 億美元：Big Pharma 到底在搶什麼？ https://drugnews.com.tw/articles/2026-07-05-big-pharma-134b-biotech-ma-en.html https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/cover.png Premium editorial cover for Big Pharma biotech M&A and late-stage pipeline acquisition analysis Big Pharma's $134 Billion M&A Rush: What Is It Really Buying? https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/figure-01.png Big Pharma buys validated time by acquiring de-risked biotech assets Big Pharma's $134 Billion M&A Rush: What Is It Really Buying? https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/figure-02.png Big Pharma now pays for de-risking rather than platform stories alone Big Pharma's $134 Billion M&A Rush: What Is It Really Buying? https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/figure-03.png Biotech M&A capital is concentrated in de-risked late-stage assets Big Pharma's $134 Billion M&A Rush: What Is It Really Buying? https://drugnews.com.tw/assets/articles/big-pharma-134b-biotech-ma-en/figure-04.png Acquisitions compress time but do not erase clinical biology risk Big Pharma's $134 Billion M&A Rush: What Is It Really Buying? https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials-en.html https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/cover.png Premium Drugnews editorial cover on HHS Operation TrialBlazer and clinical-trial reform Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/figure-01.png IND to first patient timeline under Operation TrialBlazer Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/figure-02.png QSP, MABEL, and NAMs in first-in-human dose selection Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/figure-03.png Late-stage evidence reset under FDA substantial evidence thinking Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials-en/figure-04.png CNPV speed, transparency, and biotech valuation catalyst Operation TrialBlazer: Why HHS Is Rewriting Clinical-Trial Rules and Biotech Competition https://drugnews.com.tw/articles/2026-07-04-hhs-operation-trialblazer-clinical-trials.html https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/cover.png 美國 HHS Operation TrialBlazer 臨床試驗改革專題封面美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了 https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/dcard-01.webp Dcard 原圖：美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了（圖 1）美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了 https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/dcard-02.png Dcard 原圖：美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了（圖 2）美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了 https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/dcard-03.png Dcard 原圖：美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了（圖 3）美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了 https://drugnews.com.tw/assets/articles/hhs-operation-trialblazer-clinical-trials/dcard-04.png Dcard 原圖：美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了（圖 4）美國 HHS 啟動 Operation TrialBlazer：臨床試驗規則要變了，新藥競爭也要變了 https://drugnews.com.tw/articles/2026-07-03-revmed-biotech-en.html https://drugnews.com.tw/assets/articles/revmed-biotech-en/cover.png English Drugnews infographic on RevMed, daraxonrasib, capital flexibility, and biotech independence RevMed Says No to Being Bought: Biotech's Independent Era https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-01.png Why RevMed is not rushing to sell RevMed Says No to Being Bought: Biotech's Independent Era https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-02.png Daraxonrasib is RevMed's independence ticket RevMed Says No to Being Bought: Biotech's Independent Era https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-03.png From single drug to RAS franchise RevMed Says No to Being Bought: Biotech's Independent Era https://drugnews.com.tw/assets/articles/revmed-biotech-en/figure-04.png Taiwan biotech paths to the next stage RevMed Says No to Being Bought: Biotech's Independent Era https://drugnews.com.tw/articles/2026-07-03-revmed-biotech.html https://drugnews.com.tw/assets/articles/revmed-biotech/cover.png 拒絕被併購的 RevMed：Biotech 的獨立時代專題封面拒絕被併購的 RevMed：Biotech 的獨立時代 https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-01.png Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 1）拒絕被併購的 RevMed：Biotech 的獨立時代 https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-02.png Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 2）拒絕被併購的 RevMed：Biotech 的獨立時代 https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-03.png Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 3）拒絕被併購的 RevMed：Biotech 的獨立時代 https://drugnews.com.tw/assets/articles/revmed-biotech/facebook-04.png Facebook 原圖：拒絕被併購的 RevMed：Biotech 的獨立時代（圖 4）拒絕被併購的 RevMed：Biotech 的獨立時代 https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp-en.html https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/cover.png English editorial cover on synthetic lethality after PARP Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-01.png Synthetic lethality targets the second survival route of cancer cells Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-02.png The next PARP is difficult because biology, druggability, and patient selection rarely align at once Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-03.png Combination therapy may turn synthetic lethality into an amplifier of stronger oncology backbones Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp-en/figure-04.png Protein degradation technologies can unlock targets that conventional inhibitors struggle to reach Synthetic Lethality After PARP: Why the Next Oncology Blockbuster Has Been So Hard to Find https://drugnews.com.tw/articles/2026-07-02-synthetic-lethality-next-parp.html https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/cover.png 合成致死、PARP、PRMT5 與精準腫瘤治療的商業分析封面合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？ https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-01.png Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 1）合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？ https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-02.png Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 2）合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？ https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-03.png Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 3）合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？ https://drugnews.com.tw/assets/articles/synthetic-lethality-next-parp/facebook-04.png Facebook 原圖：合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？（圖 4）合成致死二十年：為什麼 PARP 之後，下一個神藥遲遲沒有出現？ https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b-en.html https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/cover.png Centanafadine ADHD Phase 3b editorial cover Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-01.png ADHD with comorbid anxiety can amplify attention, emotion, and executive-function challenges Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-02.png Centanafadine is designed to modulate norepinephrine, dopamine, and serotonin signaling pathways Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-03.png Once-daily extended-release therapy aims to provide steadier symptom coverage across daily life Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b-en/figure-04.png Taiwan ADHD medication access involves imported drugs, generics, supply stability, and regional licensing Centanafadine’s Phase 3b Win: Why ADHD Treatment Is Moving Beyond Discipline and Toward Neurobiology https://drugnews.com.tw/articles/2026-07-01-adhd-centanafadine-phase3b.html https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/cover.png ADHD 新藥 centanafadine IIIb 期成功專題封面摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳 https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-01.png ADHD 與焦慮共病，常讓注意力、情緒與執行功能問題互相放大摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳 https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-02.png Centanafadine 同時調節正腎上腺素、多巴胺與血清素相關神經傳導路徑摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳 https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-03.png 每日一次延釋膠囊的治療目標，是讓症狀控制更穩定覆蓋日常生活摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳 https://drugnews.com.tw/assets/articles/adhd-centanafadine-phase3b/figure-04.png 台灣 ADHD 用藥可近性，牽涉進口、學名藥、供應穩定與區域授權布局摒棄「鐵拳教育」：ADHD 新藥 centanafadine IIIb 期成功，上市只差臨門一腳 https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback-en.html https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-01.png Figure 01: Two near-market lung-cancer entry points in ROS1 and ALK GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-02.png Figure 02: Why GSK returned to oncology after stepping away from the field GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-03.png Figure 03: The Miels playbook combines large M&A, mid-sized acquisitions, and global BD GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback-en/figure-04.png Figure 04: Buying assets is not the same as selling drugs GSK Goes Big: The $10.6B Nuvalent Deal Is Not Just a Lung-Cancer Pipeline Buy https://drugnews.com.tw/articles/2026-06-30-gsk-nuvalent-oncology-comeback.html https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/cover.png GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌專題封面 GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌 https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-01.png Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 1） GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌 https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-02.png Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 2） GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌 https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-03.png Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 3） GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌 https://drugnews.com.tw/assets/articles/gsk-nuvalent-oncology-comeback/facebook-04.png Facebook 原圖：GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌（圖 4） GSK 上強度：106 億美元買下 Nuvalent，不只是補肺癌管線，而是重返腫瘤牌桌 https://drugnews.com.tw/articles/2026-06-29-biotech-ipo-en.html https://drugnews.com.tw/assets/articles/biotech-ipo-en/cover-gpt-v3.png Parabilis Medicines IPO and the return of clinical-asset logic The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors https://drugnews.com.tw/assets/articles/biotech-ipo-en/figure-01-gpt-v3.png Helicons sit between small molecules and biologics The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors https://drugnews.com.tw/assets/articles/biotech-ipo-en/figure-02-gpt-v3.png Zolucatetide targets the beta-catenin TCF interaction The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors https://drugnews.com.tw/assets/articles/biotech-ipo-en/figure-03-gpt-v3.png Regeneron collaboration validates the Helicon platform strategy The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors https://drugnews.com.tw/assets/articles/biotech-ipo-en/figure-04-gpt-v3.png Technology, clinical data, capital, and timing lined up The Largest Biotech IPO in US Market History: What Parabilis Is Really Teaching Investors https://drugnews.com.tw/articles/2026-06-29-biotech-ipo.html https://drugnews.com.tw/assets/articles/biotech-ipo/cover.png 美股迎來史上最大 Biotech IPO 專題封面美股迎來史上最大 Biotech IPO https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-01.png Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 1）美股迎來史上最大 Biotech IPO https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-02.png Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 2）美股迎來史上最大 Biotech IPO https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-03.png Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 3）美股迎來史上最大 Biotech IPO https://drugnews.com.tw/assets/articles/biotech-ipo/facebook-04.png Facebook 原圖：美股迎來史上最大 Biotech IPO（圖 4）美股迎來史上最大 Biotech IPO https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound-en.html https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/cover.png FDA regulatory shift and biotech rebound editorial cover The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-01.png Operation TrialBlazer and biotech valuation logic The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-02.png Moderna mRNA flu vaccine risk benefit shift The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-03.png uniQure AMT-130 rare disease regulatory path The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound-en/figure-04.png REGENXBIO Navsunli rare disease review signal The FDA Tone Has Shifted: Why Biotech’s Rebound Is Starting at the Regulatory Layer https://drugnews.com.tw/articles/2026-06-28-fda-regulatory-shift-biotech-rebound.html https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/cover.svg FDA 審查風向與 Biotech 反攻訊號專題封面 FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起 https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-01.png Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 1） FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起 https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-02.png Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 2） FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起 https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-03.png Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 3） FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起 https://drugnews.com.tw/assets/articles/fda-regulatory-shift-biotech-rebound/facebook-04.png Facebook 原圖：FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起（圖 4） FDA 風向變了：Biotech 反攻訊號，正在從監管端亮起 https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination-en.html https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/cover.png Pancreatic cancer combination therapy cover: RAS, PRMT5, MAT2A Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-01.png English figure: RAS inhibition plus MTAP-selective PRMT5 targeting in pancreatic cancer Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-02.png English figure: early efficacy signal versus safety and dose questions Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-03.png English figure: IDEAYA's PRMT5/MTA and MAT2A strategy Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination-en/figure-04.png English figure: RAS plus PRMT5 plus MAT2A triplet rationale Pancreatic Cancer Breakthrough: After RAS Inhibitors, PRMT5/MAT2A Combinations Open the Next Layer of Upside https://drugnews.com.tw/articles/2026-06-27-pancreatic-cancer-ras-prmt5-mat2a-combination.html https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/cover-generated.svg 胰臟癌 RAS PRMT5 MAT2A 聯合療法專題封面胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開 https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-01.png Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 1）胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開 https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-02.png Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 2）胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開 https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-03.png Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 3）胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開 https://drugnews.com.tw/assets/articles/pancreatic-cancer-ras-prmt5-mat2a-combination/facebook-04.png Facebook 原圖：胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開（圖 4）胰臟癌再爆：RAS 抑制劑之後，PRMT5／MAT2A 聯合療法把想像空間再打開 https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism-en.html https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/cover.png English BioRender-style card explaining tirzepatide and immunometabolism Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path? https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-01.png Tirzepatide moves into immunometabolism Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path? https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-02.png Combination trial logic for Zepbound and Taltz Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path? https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-03.png Immunometabolism loop between obesity and inflammation Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path? https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism-en/figure-04.png Commercial logic for Lilly's tirzepatide expansion Tirzepatide Enters Autoimmune Disease: Is Immunometabolism Lilly's Next Expansion Path? https://drugnews.com.tw/articles/2026-06-26-tirzepatide-autoimmune-immunometabolism.html https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/cover-generated.svg Tirzepatide 進軍自體免疫與免疫代謝治療分析封面神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？ https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-01.png Facebook 原圖：神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 1）神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？ https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-02.png Facebook 原圖：神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 2）神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？ https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-03.png Facebook 原圖：神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 3）神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？ https://drugnews.com.tw/assets/articles/tirzepatide-autoimmune-immunometabolism/facebook-04.png Facebook 原圖：神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？（圖 4）神藥猛健樂 Tirzepatide 進軍自體免疫，只差臨門一腳？ https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform-en.html https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform-en/cover.png Companion-animal precision medicine platform cover for Protect Biotech Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform-en/figure-01-en.png Protect Biotech pet precision medicine platform Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform-en/figure-02-en.png Protect Biotech market size and platform valuation scenarios Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform-en/figure-03-en.png Protect Biotech closed-loop ecosystem from diagnostics to treatment and data feedback Toward the “Roche of Pet Medicine”: Protect Biotech’s Platform Bet https://drugnews.com.tw/articles/2026-06-25-protect-pet-medical-roche-platform.html https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform/cover.png 寶泰生醫寵物重症醫療平台與診斷治療閉環封面邁向「寵物醫療界羅氏」的寶泰生醫 https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform/word-figure-01.png 寶泰生醫平台型寵物醫療投資邏輯圖邁向「寵物醫療界羅氏」的寶泰生醫 https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform/word-figure-02.png 寶泰生醫市值想像與寵物醫療平台估值圖邁向「寵物醫療界羅氏」的寶泰生醫 https://drugnews.com.tw/assets/articles/protect-pet-medical-roche-platform/word-figure-03.png 寶泰生醫診斷、治療與獸醫院資料回流閉環圖邁向「寵物醫療界羅氏」的寶泰生醫 https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu-en.html https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/cover.png AI-designed drug enters a real clinical exam Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-01.png Psoriasis efficacy bar from PASI 75 to PASI 100 Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-02.png AI design path from modeling to clinical asset Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-03.png TYK2 as a narrow immune signaling gate Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu-en/figure-04.png Commercial exam for oral psoriasis therapies Is the First AI-Designed Drug Finally Arriving? Takeda's Zasocitinib Beats Sotyktu Head-to-Head https://drugnews.com.tw/articles/2026-06-24-ai-zasocitinib-sotyktu.html https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/cover.svg AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu 專題封面 AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-01.webp Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 1） AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-02.webp Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 2） AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-03.png Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 3） AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu https://drugnews.com.tw/assets/articles/ai-zasocitinib-sotyktu/dcard-04.png Dcard 原圖：AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu（圖 4） AI製藥，第一藥終於要來了嗎？武田 Zasocitinib 頭對頭打敗 Sotyktu https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition-en.html https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/cover-generated.png Obesity-drug market competition and next-generation metabolic medicine cover The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk? https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-01.png Product-portfolio battle The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk? https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-02.png A third player needs asymmetry The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk? https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-03.png Pfizer's opening The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk? https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition-en/figure-04.png Roche's two-axis strategy The Race for the Third Obesity-Drug Giant: Who Comes After Lilly and Novo Nordisk? https://drugnews.com.tw/articles/2026-06-22-obesity-drug-third-place-competition.html https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/cover-generated.png 減重藥第三名競爭與代謝藥物市場專題封面減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？ https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-01.png Facebook 原圖：減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？（圖 1）減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？ https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-02.png Facebook 原圖：減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？（圖 2）減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？ https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-03.png Facebook 原圖：減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？（圖 3）減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？ https://drugnews.com.tw/assets/articles/obesity-drug-third-place-competition/facebook-04.png Facebook 原圖：減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？（圖 4）減重藥「第三名」爭奪戰：禮來與諾和諾德之外，誰能成為下一個代謝巨頭？ https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda-en.html https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/cover.png Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-01.png Why MK-2010 matters Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-02.png HARMONi-6 changed tone Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda-en/figure-03.png Next oncology package Merck's Shift on PD-1/VEGF Bispecifics: Keytruda Still Rules, but the Next IO Backbone Is Getting Closer https://drugnews.com.tw/articles/2026-06-21-merck-pd1-vegf-mk2010-keytruda.html https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/cover-generated.svg 默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近專題封面默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近 https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-01.png Facebook 原圖：默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 1）默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近 https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-02.png Facebook 原圖：默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 2）默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近 https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-03.png Facebook 原圖：默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 3）默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近 https://drugnews.com.tw/assets/articles/merck-pd1-vegf-mk2010-keytruda/facebook-04.png Facebook 原圖：默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近（圖 4）默沙東對 PD-1／VEGF 雙抗改口：Keytruda 王座還在，但下一代免疫底盤已經逼近 https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury-en.html https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/cover.png Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-01.png Biotech treasury shock Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-02.png Why it matters Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury-en/figure-03.png The real test Enlivex's RAIN Token Windfall: When a Biotech Balance Sheet Starts Looking Like Crypto Treasury Strategy https://drugnews.com.tw/articles/2026-06-20-enlivex-rain-token-biotech-treasury.html https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury/cover-generated.svg 【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】專題封面【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】 https://drugnews.com.tw/assets/articles/enlivex-rain-token-biotech-treasury/facebook-01.png Facebook 原圖：【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】（圖 1）【Enlivex 的幣圈豪賭：Biotech 沒收入，卻靠 RAIN 代幣賺出 12 億美元帳面利潤】 https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en.html https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en/cover.png GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en/figure-01.png What GSK bought GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en/figure-02.png Precision oncology moat GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis-en/figure-03.png BD logic GSK's US$10.6 Billion Nuvalent Deal Is Really a Bet on Resistance and Brain Metastases https://drugnews.com.tw/articles/2026-06-19-gsk-nuvalent-lung-cancer-resistance-brain-metastasis.html https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/cover-generated.svg GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法專題封面 GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法 https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-01.png Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 1） GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法 https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-02.png Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 2） GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法 https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-03.png Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 3） GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法 https://drugnews.com.tw/assets/articles/gsk-nuvalent-lung-cancer-resistance-brain-metastasis/facebook-04.png Facebook 原圖：GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法（圖 4） GSK 用 106 億美元買下 Nuvalent：真正買的不是三條肺癌管線，而是「耐藥與腦轉移」的下一代解法 https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy.html https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/cover-generated.svg GLP-1 頭對頭競爭與代謝健康管理專題封面 GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-01.jpg Facebook 原圖：Ecnoglutide 與 Wegovy 頭對頭減重資料整理 GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-02.jpg Facebook 原圖：藥時事與 CMoney 減肥藥賽道投資課程 GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-03.jpg Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-04.jpg Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy/facebook-05.jpg Facebook 原圖：GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ GLP-1「頭對頭」大戰：輝瑞＆諾和諾德必有一戰？ https://drugnews.com.tw/articles/2026-06-17-glp1-head-to-head-ecnoglutide-wegovy-en.html https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/cover.png Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-01.png Head-to-head signal Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-02.png What really matters Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King https://drugnews.com.tw/assets/articles/glp1-head-to-head-ecnoglutide-wegovy-en/figure-03.png Wegovy moat Ecnoglutide Versus Wegovy: A 20-Week Head-to-Head Signal Is Not the Same as a New GLP-1 King https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine-en.html https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/cover.png Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies? Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies? https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-01.png Beyond obesity Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies? https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-02.png Why vaccines? Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies? https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine-en/figure-03.png Capital allocation Why Would Lilly, the Obesity-Drug Giant, Spend US$3.8 Billion on Vaccine Companies? https://drugnews.com.tw/articles/2026-06-16-lilly-vaccine-acquisitions-prevention-medicine.html https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/cover-generated.png 禮來用 GLP-1 現金流布局疫苗與預防醫學的專題封面禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？ https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-01.jpg Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 1）禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？ https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-02.jpg Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 2）禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？ https://drugnews.com.tw/assets/articles/lilly-vaccine-acquisitions-prevention-medicine/facebook-03.jpg Facebook 原圖：禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？（圖 3）禮來 38 億美元買三家疫苗公司：減肥藥巨頭，為什麼突然回頭買「預防醫學」？ https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t-en.html https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/cover.png ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-01.png ASCO signal ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-02.png Practice-changing data ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle https://drugnews.com.tw/assets/articles/2026-asco-car-t-en/figure-03.png Platform competition ASCO 2026: RAS, ADCs, Bispecifics, and In Vivo CAR-T Point to a New Oncology Cycle https://drugnews.com.tw/articles/2026-06-15-2026-asco-car-t.html https://drugnews.com.tw/assets/articles/2026-asco-car-t/cover-generated.png 2026 ASCO 腫瘤治療多平台突破專題封面 2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代 https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-01.jpg Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 1） 2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代 https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-02.jpg Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 2） 2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代 https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-03.jpg Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 3） 2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代 https://drugnews.com.tw/assets/articles/2026-asco-car-t/facebook-04.jpg Facebook 原圖：2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代（圖 4） 2026 ASCO：生存期翻倍、體內 CAR-T 破局，腫瘤治療正在換一個時代 https://drugnews.com.tw/articles/2026-06-14-revolution-medicines-en.html https://drugnews.com.tw/assets/articles/revolution-medicines-en/cover.png Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-01.png RAS value creation Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-02.png Financing rhythm Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science https://drugnews.com.tw/assets/articles/revolution-medicines-en/figure-03.png Science x capital Revolution Medicines: Why Biotech Winners Need Capital Strategy, Not Just Good Science https://drugnews.com.tw/articles/2026-06-14-revolution-medicines.html https://drugnews.com.tw/assets/articles/revolution-medicines/cover.svg Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑專題封面 Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑 https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-01.webp Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 1） Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑 https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-02.png Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 2） Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑 https://drugnews.com.tw/assets/articles/revolution-medicines/dcard-03.png Dcard 原圖：Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑（圖 3） Revolution Medicines 神話：會研發還不夠，會融資才撐得過新藥長跑 https://drugnews.com.tw/articles/2026-06-13-anhorn-ai-drug-development-en.html https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/cover-ai-drug-survival.png AI drug development clinical asset engine cover The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-01.png Figure 1 | The next phase of AI drug development: from molecular generation to drug survival, human translation, and clinical asset creation The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-02.png Figure 2 | Three consecutive years in the NVIDIA ecosystem: from platform visibility to AI-native clinical asset positioning The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-03.png Figure 3 | The AI drug-development deal wave: Big Pharma is buying platforms, data, and clinical asset generation capability The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-04.png Figure 4 | AnHorn’s capital efficiency and three-layer closed-loop engine: US$11M, two clinical assets, and US$5.5M per clinical asset The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-05.png Figure 5 | AnHorn’s AI+PROTAC druggability flywheel: from disease biology to human translation and multi-asset replication The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/assets/articles/anhorn-ai-drug-development-en/figure-06.png Figure 6 | Representative AI-native drug development progress: company, asset, modality, speed, clinical stage, and indication The Next Phase of AI Drug Development: Making Molecules Survive as Drugs https://drugnews.com.tw/articles/2026-06-13-dcard-261654701.html https://drugnews.com.tw/assets/articles/dcard-261654701/cover-ai-drug-survival.png AI製藥下半場：讓藥活下來專題封面 AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-01.webp Dcard 原圖：AI製藥下半場：讓藥活下來（圖 1） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-02.png Dcard 原圖：AI製藥下半場：讓藥活下來（圖 2） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-03.png Dcard 原圖：AI製藥下半場：讓藥活下來（圖 3） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-04.png Dcard 原圖：AI製藥下半場：讓藥活下來（圖 4） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-05.png Dcard 原圖：AI製藥下半場：讓藥活下來（圖 5） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/assets/articles/dcard-261654701/dcard-06.png Dcard 原圖：AI製藥下半場：讓藥活下來（圖 6） AI製藥下半場：讓藥活下來 https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612-en.html https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/cover-ai-drug-discovery.jpg AI drug discovery pipeline and clinical development cover image Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-01-ai-pipeline-en.png AI drug discovery pipeline map with Zasocitinib, GB-0895, Zovegalisib, and REC-4881 Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-02-ai-capabilities-en.png Four core capabilities behind AI drug discovery Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612-en/figure-03-ai-asset-value-en.png AI drug discovery from model hype to clinical asset value Where Does AI Drug Discovery Stand Now? A Pipeline-Based Reality Check https://drugnews.com.tw/articles/2026-06-12-ai-drug-discovery-pipeline-20260612.html https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/cover-ai-drug-discovery.jpg AI 製藥管線與臨床開發示意封面盤點整理，AI藥物開發走得如何了？ https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-01.webp Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 1）盤點整理，AI藥物開發走得如何了？ https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-02.png Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 2）盤點整理，AI藥物開發走得如何了？ https://drugnews.com.tw/assets/articles/ai-drug-discovery-pipeline-20260612/dcard-03.png Dcard 原圖：盤點整理，AI藥物開發走得如何了？（圖 3）盤點整理，AI藥物開發走得如何了？ https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle-en.html https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/cover.png GLP-1 Is Reshaping Biotech Capital Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/figure-01.png Capital Is Moving Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/figure-02.png From Drug to Ecosystem Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/figure-03.png BD Repricing Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle-en/figure-04.png Investor Question Obesity Becomes King: How GLP-1 Is Reshuffling Global Biotech Capital https://drugnews.com.tw/articles/2026-06-11-glp1-biotech-capital-reshuffle.html https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/cover-glp1-capital.png GLP-1 重新分配全球生技資本與研發資源的視覺封面減肥成王：GLP-1 正在把全球生技資本重新洗牌 https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-01.png GLP-1 抽走生技資本注意力，重新改寫腫瘤與代謝賽道的資源配置。減肥成王：GLP-1 正在把全球生技資本重新洗牌 https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-02.jpg 藥時事與 CMoney 全曜財經共同打造減肥藥賽道投資課程。減肥成王：GLP-1 正在把全球生技資本重新洗牌 https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-03.png 晚期研發報酬率回升背後，肥胖症資產成為大型藥廠管線價值的重要來源。減肥成王：GLP-1 正在把全球生技資本重新洗牌 https://drugnews.com.tw/assets/articles/glp1-biotech-capital-reshuffle/dcard-04.png GLP-1 不只是減重題材，而是牽動產能、BD、估值與資本配置的產業變數。減肥成王：GLP-1 正在把全球生技資本重新洗牌 https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer-en.html https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/cover.png RAS Resistance Management: Where CX-5461 Could Matter RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-01.png RAS Opens the Door RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-02.png Escape Pathways RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-03.png CX-5461 Positioning RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer-en/figure-04.png What to Track RAS Targeting Opens a New Pancreatic-Cancer Window: How Senhwa's CX-5461 Positions for the Next Resistance-Management War https://drugnews.com.tw/articles/2026-06-10-sinphar-cx5461-ras-pancreatic-cancer.html https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer/cover-cancer-cell.png 胰臟癌細胞與精準治療示意封面圖 RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰 https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer/dcard-01.png RAS 標靶打開胰臟癌新局：Daraxonrasib 讓胰臟癌正式走向 RAS 標靶治療時代，下一場戰爭是抗藥性管理。 RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰 https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer/dcard-02.png RAS 被壓下去後，癌細胞可能轉向 MYC、KEAP1 / NRF2、YAP / TAZ / TEAD、腫瘤微環境重塑與免疫逃脫路徑。 RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰 https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer/dcard-03.png CX-5461 不是取代 RAS 抑制劑，而是透過核糖體壓力、DNA 損傷壓力與免疫活化，補上下一代聯合治療候選夥伴的拼圖。 RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰 https://drugnews.com.tw/assets/articles/sinphar-cx5461-ras-pancreatic-cancer/dcard-04.png 生華科 CX-5461 接下來要看的，是 RAS 抗藥性管理與 HRD / PARP 抗藥兩條價值線，以及試驗啟動收案、KRAS 陽性訊號與生物標記策略三個臨床追蹤節點。 RAS 標靶打開胰臟癌新局：生華科 CX-5461 卡位下一場「抗藥性管理」戰 https://drugnews.com.tw/articles/2026-06-10-biotech-ir-capital-market-story.html https://drugnews.com.tw/assets/articles/biotech-ir-capital-market-story/ir-flow.svg 生醫 IR 溝通流程：公開資訊、科學轉譯、資本市場故事、後續追蹤生醫公司 IR 不是把簡報變漂亮，而是把管線變成可追蹤的資本市場故事 https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition-en.html https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition-en/cover.png The Real Prize in Radiopharma M&A The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition-en/figure-01.png Radiopharma Is a Platform Game The US$7 Billion Radiopharma Deal Rumor: Curium Wants Lantheus, but the Real Prize Is a Ticket to the Nuclear-Medicine Era https://drugnews.com.tw/articles/2026-06-09-curium-lantheus-radiopharma-acquisition.html https://drugnews.com.tw/assets/articles/curium-lantheus-radiopharma-acquisition/dcard-01.png Curium 與 Lantheus 的併購傳聞，重點不只是產品，而是核藥平台能力與院端入口。 70億美元核藥併購傳聞：Curium想買Lantheus，真正買的是一張核藥時代的入場券 https://drugnews.com.tw/articles/2026-06-08-cart-autoimmune-new-era.html https://drugnews.com.tw/assets/articles/cart-autoimmune-new-era/dcard-01.png Kyverna 的 miv-cel 推動 CAR-T 從血癌治療走向自體免疫疾病，SPS 是第一個商業化門口。 CAR-T 迎接新時代：從血癌走向自體免疫 https://drugnews.com.tw/articles/2026-06-07-pharma-ai-capability-future.html https://drugnews.com.tw/assets/articles/pharma-ai-capability-future/dcard-01.png AI 正在把新藥研發從手工試錯推向系統化、模型化、資料化的新型研發工廠。沒有 AI 能力的藥廠，將不再被稱作藥廠 https://drugnews.com.tw/articles/2026-06-06-old-targets-differentiation-strategy.html https://drugnews.com.tw/assets/articles/old-targets-differentiation-strategy/dcard-01.webp 熱門靶點擁擠不代表沒有價值；真正關鍵是身位、差異化、適應症切入與 BD 對接能力。老靶點都很捲，但不是不能賺錢 https://drugnews.com.tw/assets/articles/old-targets-differentiation-strategy/dcard-02.png 在紅海靶點裡，產品能否賺錢取決於是否具備新武器、錯位戰場與清楚的資本配置策略。老靶點都很捲，但不是不能賺錢 https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery.html https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-01.webp 外用 JAK 抑制劑的勝負不只在靶點，而在皮膚穿透、局部濃度與全身暴露的平衡。從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？ https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-02.png Ruxolitinib、delgocitinib 與前藥策略代表外用 JAK 抑制劑的不同開發路徑。從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？ https://drugnews.com.tw/assets/articles/topical-jak-inhibitor-skin-delivery/dcard-03.png 台灣公司若切入外用 JAK 賽道，關鍵是特定適應症定位、臨床驗證與國際授權故事。從 Ruxolitinib cream 說起：外用 JAK 抑制劑，為什麼不是每個分子都能做？ https://drugnews.com.tw/articles/2026-06-04-retatrutide-obesity-surgery-level-weight-loss.html https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-01.webp Retatrutide 透過 GIP、GLP-1 與 glucagon 三重受體機制，把肥胖治療推向接近手術級別的減重幅度。 Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場 https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-02.webp 肥胖藥物競爭已從單純降體重，進入代謝改善、長期維持、安全性與商業化定位的綜合戰場。 Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場 https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-03.png Eli Lilly 的三重受體策略，正在重新拉高 GLP-1 類藥物後續競爭門檻。 Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場 https://drugnews.com.tw/assets/articles/retatrutide-obesity-surgery-level-weight-loss/dcard-04.png 當藥物療效逼近減重手術，醫療支付、慢病管理與藥廠估值邏輯都會被重新定義。 Retatrutide 殺進減重手術級別：禮來三重受體藥物，把肥胖治療推向新戰場 https://drugnews.com.tw/articles/2026-06-03-aatd-new-therapy-rna-gene-editing.html https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-01.webp AATD 治療正在從傳統補蛋白，走向長效重組蛋白、RNA 編輯與基因編輯並行的新競賽。 40年沒藥的遺傳病迎來重磅進展 https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-02.webp Sanofi、Wave 與 Beam 分別代表不同技術路徑，也對應不同的風險、療效與商業化想像。 40年沒藥的遺傳病迎來重磅進展 https://drugnews.com.tw/assets/articles/aatd-new-therapy-rna-gene-editing/dcard-03.png 罕見遺傳病的下一階段，不只是補足缺失蛋白，而是能否安全、持久地修正疾病根源。 40年沒藥的遺傳病迎來重磅進展 https://drugnews.com.tw/articles/2026-06-02-biogen-alzheimers-tau-biib080-strategy.html https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-01.webp Biogen 押注 tau 靶點，代表 AD 研發在 amyloid 之外仍尋找能改變疾病進程的新路徑。 Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？ https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-02.png BIIB080 / diranersen 的關鍵不只是單一試驗結果，而是 ASO 能否真正影響 tau 生成與臨床進展。 Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？ https://drugnews.com.tw/assets/articles/biogen-alzheimers-tau-biib080-strategy/dcard-03.png 阿茲海默症研發的高風險，來自龐大需求、複雜病理與臨床終點不確定性的交會。 Biogen 孤注一擲：Alzheimer’s Disease 研發墳場裡，tau 靶點能不能走出新路？ https://drugnews.com.tw/articles/2026-06-01-pluvicto-radioligand-therapy-growth.html https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-01.webp Pluvicto 的銷售成長，代表 PSMA 放射配體療法已從小眾核醫技術走向攝護腺癌精準治療主戰場。核藥賣爆了 https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-02.webp 攝護腺癌治療正在從荷爾蒙訊號攻防，走向基因分型、蛋白降解與核醫診療一體化。核藥賣爆了 https://drugnews.com.tw/assets/articles/pluvicto-radioligand-therapy-growth/dcard-03.png 核藥商業化的關鍵，不只在分子設計，也在製造、配送、院端流程與適應症擴張。核藥賣爆了 https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-01.webp Dcard 原圖：Tavneos 危機與撤市風險總覽 ⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣 https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-02.png Dcard 原圖：Tavneos 資料完整性與 FDA 指控 ⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣 https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-03.png Dcard 原圖：Tavneos 罕病藥監管教訓 ⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣 https://drugnews.com.tw/articles/2026-05-30-drug-combination-efficacy-doubling.html https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-01.webp Dcard 原圖：藥王的最佳搭檔？療效翻倍！藥王的最佳搭檔？療效翻倍！ https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-02.png Dcard 原圖：藥王的最佳搭檔？療效翻倍！藥王的最佳搭檔？療效翻倍！ https://drugnews.com.tw/assets/articles/drug-combination-efficacy-doubling/dcard-03.png Dcard 原圖：藥王的最佳搭檔？療效翻倍！藥王的最佳搭檔？療效翻倍！ https://drugnews.com.tw/articles/2026-05-29-next-generation-obesity-therapy-directions.html https://drugnews.com.tw/assets/articles/next-generation-obesity-therapy-directions/dcard-01.webp Dcard 原圖：減重藥物不只看體重了：下一代療法正在瞄準這些方向減重藥物不只看體重了：下一代療法正在瞄準這些方向 https://drugnews.com.tw/assets/articles/next-generation-obesity-therapy-directions/dcard-02.webp Dcard 原圖：減重藥物不只看體重了：下一代療法正在瞄準這些方向減重藥物不只看體重了：下一代療法正在瞄準這些方向 https://drugnews.com.tw/assets/articles/next-generation-obesity-therapy-directions/dcard-03.png Dcard 原圖：減重藥物不只看體重了：下一代療法正在瞄準這些方向減重藥物不只看體重了：下一代療法正在瞄準這些方向 https://drugnews.com.tw/assets/articles/next-generation-obesity-therapy-directions/dcard-04.png Dcard 原圖：減重藥物不只看體重了：下一代療法正在瞄準這些方向減重藥物不只看體重了：下一代療法正在瞄準這些方向 https://drugnews.com.tw/articles/2026-05-28-biotech-investment-judgment-system.html https://drugnews.com.tw/assets/articles/biotech-investment-judgment-system/dcard-01.webp Dcard 原圖：生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統 🧬 生技投資圈｜不是更多新聞，是一套生技醫藥判斷系統 https://drugnews.com.tw/articles/2026-05-27-taiwan-biotech-valuation-framework.html https://drugnews.com.tw/assets/articles/taiwan-biotech-valuation-framework/valuation-map.svg 台灣生技估值框架：先分辨公司資產類型，再選模型與追蹤事件。台灣生技估值第一步：不要把所有公司都塞進同一個本益比 https://drugnews.com.tw/articles/2026-05-27-generic-pharma-transformation-anxiety.html https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-01.webp Dcard 原圖：太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮 https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-02.png Dcard 原圖：太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮 https://drugnews.com.tw/assets/articles/generic-pharma-transformation-anxiety/dcard-03.png Dcard 原圖：太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮太陽製藥、梯瓦製藥與全球學名藥廠的轉型焦慮 https://drugnews.com.tw/articles/2026-05-26-weight-loss-side-effect-new-track.html https://drugnews.com.tw/assets/articles/weight-loss-side-effect-new-track/dcard-01.webp Dcard 原圖：減肥藥新副作用，意外帶出新賽道？減肥藥新副作用，意外帶出新賽道？ https://drugnews.com.tw/assets/articles/weight-loss-side-effect-new-track/dcard-02.webp Dcard 原圖：減肥藥新副作用，意外帶出新賽道？減肥藥新副作用，意外帶出新賽道？ https://drugnews.com.tw/assets/articles/weight-loss-side-effect-new-track/dcard-03.png Dcard 原圖：減肥藥新副作用，意外帶出新賽道？減肥藥新副作用，意外帶出新賽道？ https://drugnews.com.tw/assets/articles/weight-loss-side-effect-new-track/dcard-04.png Dcard 原圖：減肥藥新副作用，意外帶出新賽道？減肥藥新副作用，意外帶出新賽道？ https://drugnews.com.tw/articles/2026-05-25-asthma-new-drug-immune-targets.html https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-01.webp Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! 氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-02.webp Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! 氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-03.jpg Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! 氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-04.jpg Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! 氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! https://drugnews.com.tw/assets/articles/asthma-new-drug-immune-targets/dcard-05.jpg Dcard 原圖：氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! 氣喘新藥正在換檔：從吸入三合一到上游免疫靶點! https://drugnews.com.tw/articles/2026-05-24-ox2r-cns-narcolepsy-opportunity.html https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-01.webp Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-02.png Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 https://drugnews.com.tw/assets/articles/ox2r-cns-narcolepsy-opportunity/dcard-03.png Dcard 原圖：OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 OX2R 爆紅：從發作性嗜睡症，到下一代 CNS 藥物想像空間 https://drugnews.com.tw/articles/2026-05-23-global-biotech-obesity-megatrend.html https://drugnews.com.tw/assets/articles/global-biotech-obesity-megatrend/dcard-01.webp Dcard 原圖：全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價全球生技大浪來襲：看懂五兆減肥藥的主升段與科學定價 https://drugnews.com.tw/articles/2026-05-22-mid-size-biotech-blockbuster-cashflow.html https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-01.webp Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流 https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-02.png Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流 https://drugnews.com.tw/assets/articles/mid-size-biotech-blockbuster-cashflow/dcard-03.png Dcard 原圖：這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流這些中型 Biotech，正在把「重磅炸彈藥物」從夢想變成現金流 https://drugnews.com.tw/articles/2026-05-21-ai-semiconductor-biotech-capital-neglect.html https://drugnews.com.tw/assets/articles/ai-semiconductor-biotech-capital-neglect/dcard-01.webp Dcard 原圖：AI半導體掩蓋生技光芒 AI半導體掩蓋生技光芒 https://drugnews.com.tw/assets/articles/ai-semiconductor-biotech-capital-neglect/dcard-02.png Dcard 原圖：AI半導體掩蓋生技光芒 AI半導體掩蓋生技光芒 https://drugnews.com.tw/articles/2026-05-20-ai-drug-discovery-google-funding.html https://drugnews.com.tw/assets/articles/ai-drug-discovery-google-funding/dcard-01.webp Dcard 原圖：破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元 https://drugnews.com.tw/assets/articles/ai-drug-discovery-google-funding/dcard-02.webp Dcard 原圖：破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元 https://drugnews.com.tw/assets/articles/ai-drug-discovery-google-funding/dcard-03.png Dcard 原圖：破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元 https://drugnews.com.tw/assets/articles/ai-drug-discovery-google-funding/dcard-04.png Dcard 原圖：破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元破紀錄 AI 製藥融資來了！Google 系公司一次募 21 億美元 https://drugnews.com.tw/articles/2026-05-19-gilead-hiv-yeztugo-prep-growth.html https://drugnews.com.tw/assets/articles/gilead-hiv-yeztugo-prep-growth/dcard-01.webp Dcard 原圖：HIV 新藥很好賺呀...吉利德財報披露 HIV 新藥很好賺呀...吉利德財報披露 https://drugnews.com.tw/assets/articles/gilead-hiv-yeztugo-prep-growth/dcard-02.png Dcard 原圖：HIV 新藥很好賺呀...吉利德財報披露 HIV 新藥很好賺呀...吉利德財報披露 https://drugnews.com.tw/assets/articles/gilead-hiv-yeztugo-prep-growth/dcard-03.png Dcard 原圖：HIV 新藥很好賺呀...吉利德財報披露 HIV 新藥很好賺呀...吉利德財報披露 https://drugnews.com.tw/articles/2026-05-18-pfizer-vepdegestrant-strategy-mistake.html https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-01.webp Dcard 原圖：大藥廠輝瑞在兩個判斷上栽跟頭？大藥廠輝瑞在兩個判斷上栽跟頭？ https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-02.png Dcard 原圖：大藥廠輝瑞在兩個判斷上栽跟頭？大藥廠輝瑞在兩個判斷上栽跟頭？ https://drugnews.com.tw/assets/articles/pfizer-vepdegestrant-strategy-mistake/dcard-03.png Dcard 原圖：大藥廠輝瑞在兩個判斷上栽跟頭？大藥廠輝瑞在兩個判斷上栽跟頭？ https://drugnews.com.tw/articles/2026-05-17-jnj-auto-car-t-commercial-challenge.html https://drugnews.com.tw/assets/articles/jnj-auto-car-t-commercial-challenge/dcard-01.webp Dcard 原圖：Johnson & Johnson（嬌生）砍掉兩條自體淋巴瘤 CAR-T Johnson & Johnson（嬌生）砍掉兩條自體淋巴瘤 CAR-T https://drugnews.com.tw/assets/articles/jnj-auto-car-t-commercial-challenge/dcard-02.png Dcard 原圖：Johnson & Johnson（嬌生）砍掉兩條自體淋巴瘤 CAR-T Johnson & Johnson（嬌生）砍掉兩條自體淋巴瘤 CAR-T https://drugnews.com.tw/articles/2026-05-17-daiichi-sankyo-adc-capacity-lesson.html https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-01.png 第一三共 ADC 產能豪賭的核心：DXd 平台爆款、後續管線、CMO 合約與小田原工廠投資，在臨床節奏修正後轉化為高額成本。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？ https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-02.png 第一三共 DXd ADC 資產與合作布局：Enhertu、Datroway、HER3-DXd、I-DXd 與 R-DXd 共同構成產能預期。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？ https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-03.png 第一三共認列的 ADC 供應鏈成本：CMO 補償費用準備金與小田原工廠 ADC 設備減損，合計約 950 億日圓。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？ https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-05.png ADC 供應鏈也需要風險折現：臨床成功率、監管時間、安全性標籤、商業化爬坡與最低採購義務都會影響產能價值。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？ https://drugnews.com.tw/assets/articles/daiichi-sankyo-adc-capacity-lesson/dcard-04.png 台灣 ADC 與 CDMO 對照：浩鼎代表 ADC 新藥開發主線，永昕代表 ADC / 生物藥製造與 CDMO 主線。第一三共最貴的一課：ADC 爆款之後，產能豪賭如何反噬？ https://drugnews.com.tw/articles/2026-05-16-fda-commissioner-resignation-regulatory-risk.html https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-01.webp Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-02.png Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 https://drugnews.com.tw/assets/articles/fda-commissioner-resignation-regulatory-risk/dcard-03.png Dcard 原圖：FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 FDA 局長黯然離職：全球最重要的新藥裁判，正在變得更不可預測 https://drugnews.com.tw/articles/2026-05-15-antidepressant-new-drugs-pipeline.html https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-01.webp Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點全網最全的「抗憂鬱新藥」最新進展盤點 https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-02.png Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點全網最全的「抗憂鬱新藥」最新進展盤點 https://drugnews.com.tw/assets/articles/antidepressant-new-drugs-pipeline/dcard-03.png Dcard 原圖：全網最全的「抗憂鬱新藥」最新進展盤點全網最全的「抗憂鬱新藥」最新進展盤點 https://drugnews.com.tw/articles/2026-05-14-pharmaessentia-besremi-mpn-valuation.html https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-01.webp Dcard 原圖：藥華藥打開估值想像空間藥華藥打開估值想像空間 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-02.png Dcard 原圖：藥華藥打開估值想像空間藥華藥打開估值想像空間 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-03.png Dcard 原圖：藥華藥打開估值想像空間藥華藥打開估值想像空間 https://drugnews.com.tw/assets/articles/pharmaessentia-besremi-mpn-valuation/dcard-04.jpg Dcard 原圖：藥華藥打開估值想像空間藥華藥打開估值想像空間 https://drugnews.com.tw/articles/2026-05-13-neuroinflammation-cns-drug-comeback.html https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-01.webp Dcard 原圖：中樞神經新藥要靠「神經發炎」？中樞神經新藥要靠「神經發炎」？ https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-02.png Dcard 原圖：中樞神經新藥要靠「神經發炎」？中樞神經新藥要靠「神經發炎」？ https://drugnews.com.tw/assets/articles/neuroinflammation-cns-drug-comeback/dcard-03.png Dcard 原圖：中樞神經新藥要靠「神經發炎」？中樞神經新藥要靠「神經發炎」？ https://drugnews.com.tw/articles/2026-05-12-jnj-autoimmune-twins-stelara-transition.html https://drugnews.com.tw/assets/articles/jnj-autoimmune-twins-stelara-transition/dcard-01.webp Dcard 原圖：自體免疫雙子星拯救嬌生自體免疫雙子星拯救嬌生 https://drugnews.com.tw/assets/articles/jnj-autoimmune-twins-stelara-transition/dcard-02.webp Dcard 原圖：自體免疫雙子星拯救嬌生自體免疫雙子星拯救嬌生 https://drugnews.com.tw/assets/articles/jnj-autoimmune-twins-stelara-transition/dcard-03.png Dcard 原圖：自體免疫雙子星拯救嬌生自體免疫雙子星拯救嬌生 https://drugnews.com.tw/articles/2026-05-11-dac-adc-protac-next-targeted-therapy.html https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-01.webp Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-02.png Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ https://drugnews.com.tw/assets/articles/dac-adc-protac-next-targeted-therapy/dcard-03.png Dcard 原圖：DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ DAC（降解劑－抗體偶聯藥物）會是下一代標靶藥物的新引爆點嗎？ https://drugnews.com.tw/articles/2026-05-10-glp1-medicare-policy-delay.html https://drugnews.com.tw/assets/articles/glp1-medicare-policy-delay/dcard-01.webp Dcard 原圖：川普放政策鴿子，減肥藥價格白降了？川普放政策鴿子，減肥藥價格白降了？ https://drugnews.com.tw/assets/articles/glp1-medicare-policy-delay/dcard-02.webp Dcard 原圖：川普放政策鴿子，減肥藥價格白降了？川普放政策鴿子，減肥藥價格白降了？ https://drugnews.com.tw/assets/articles/glp1-medicare-policy-delay/dcard-03.png Dcard 原圖：川普放政策鴿子，減肥藥價格白降了？川普放政策鴿子，減肥藥價格白降了？ https://drugnews.com.tw/articles/2026-05-09-clinical-trial-fraud-fda-withdrawal.html https://drugnews.com.tw/assets/articles/clinical-trial-fraud-fda-withdrawal/dcard-01.webp Dcard 原圖：臨床試驗作假，FDA 撤市風暴！臨床試驗作假，FDA 撤市風暴！ https://drugnews.com.tw/assets/articles/clinical-trial-fraud-fda-withdrawal/dcard-02.webp Dcard 原圖：臨床試驗作假，FDA 撤市風暴！臨床試驗作假，FDA 撤市風暴！ https://drugnews.com.tw/assets/articles/clinical-trial-fraud-fda-withdrawal/dcard-03.png Dcard 原圖：臨床試驗作假，FDA 撤市風暴！臨床試驗作假，FDA 撤市風暴！ https://drugnews.com.tw/assets/articles/clinical-trial-fraud-fda-withdrawal/dcard-04.png Dcard 原圖：臨床試驗作假，FDA 撤市風暴！臨床試驗作假，FDA 撤市風暴！ https://drugnews.com.tw/articles/2026-05-08-lilly-tirzepatide-glp1-growth.html https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-01.webp Dcard 原圖：減肥藥還是太強了，禮來猛健樂賺爛！減肥藥還是太強了，禮來猛健樂賺爛！ https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-02.png Dcard 原圖：減肥藥還是太強了，禮來猛健樂賺爛！減肥藥還是太強了，禮來猛健樂賺爛！ https://drugnews.com.tw/assets/articles/lilly-tirzepatide-glp1-growth/dcard-03.png Dcard 原圖：減肥藥還是太強了，禮來猛健樂賺爛！減肥藥還是太強了，禮來猛健樂賺爛！ https://drugnews.com.tw/articles/2026-05-07-pan-ras-patent-safety-war.html https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-01.webp Dcard 原圖：下一代世紀大藥的陰影？下一代世紀大藥的陰影？ https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-02.png Dcard 原圖：下一代世紀大藥的陰影？下一代世紀大藥的陰影？ https://drugnews.com.tw/assets/articles/pan-ras-patent-safety-war/dcard-03.png Dcard 原圖：下一代世紀大藥的陰影？下一代世紀大藥的陰影？ https://drugnews.com.tw/articles/2026-05-06-taipei-biotech-npv-workshop.html https://drugnews.com.tw/assets/articles/taipei-biotech-npv-workshop/dcard-01.webp Dcard 原圖：【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點【限時免費－台北場】藥時事｜捕捉生技飆股：用NPV框架算出翻倍重估點 https://drugnews.com.tw/articles/2026-05-05-pharma-pipeline-bd-attraction.html https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-01.webp Dcard 原圖：讓大藥廠心動的管線到底做了什麼？讓大藥廠心動的管線到底做了什麼？ https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-02.png Dcard 原圖：讓大藥廠心動的管線到底做了什麼？讓大藥廠心動的管線到底做了什麼？ https://drugnews.com.tw/assets/articles/pharma-pipeline-bd-attraction/dcard-03.png Dcard 原圖：讓大藥廠心動的管線到底做了什麼？讓大藥廠心動的管線到底做了什麼？ https://drugnews.com.tw/articles/2026-05-04-hair-growth-drug-breakthrough.html https://drugnews.com.tw/assets/articles/hair-growth-drug-breakthrough/dcard-01.webp Dcard 原圖：最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？ https://drugnews.com.tw/assets/articles/hair-growth-drug-breakthrough/dcard-02.webp Dcard 原圖：最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？ https://drugnews.com.tw/assets/articles/hair-growth-drug-breakthrough/dcard-03.png Dcard 原圖：最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？最強生髮藥暴漲 47%，為什麼可能改寫掉髮治療三十年僵局？ https://drugnews.com.tw/articles/2026-05-03-in-vivo-cart-kelonia-lilly.html https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-01.webp Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？ https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-02.webp Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？ https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-03.png Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？ https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-04.png Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？ https://drugnews.com.tw/assets/articles/in-vivo-cart-kelonia-lilly/dcard-05.png Dcard 原圖：體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？體內 CAR-T 的泡沫，還是下一代細胞治療最貴的門票？ https://drugnews.com.tw/articles/2026-05-02-sun-pharma-organon-acquisition.html https://drugnews.com.tw/assets/articles/sun-pharma-organon-acquisition/dcard-01.webp Dcard 原圖：印度製藥巨頭的野望！併購美國藥廠！印度製藥巨頭的野望！併購美國藥廠！ https://drugnews.com.tw/articles/2026-05-01-alzheimers-amyloid-hypothesis-collapse.html https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-01.webp Dcard 原圖：阿茲海默症20年來的假說開始崩盤？阿茲海默症20年來的假說開始崩盤？ https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-02.webp Dcard 原圖：阿茲海默症20年來的假說開始崩盤？阿茲海默症20年來的假說開始崩盤？ https://drugnews.com.tw/assets/articles/alzheimers-amyloid-hypothesis-collapse/dcard-03.png Dcard 原圖：阿茲海默症20年來的假說開始崩盤？阿茲海默症20年來的假說開始崩盤？ https://drugnews.com.tw/articles/2026-04-30-amazon-ai-nvidia.html https://drugnews.com.tw/assets/articles/amazon-ai-nvidia/dcard-01.webp Dcard 原圖：亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia）（圖 1）亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia） https://drugnews.com.tw/assets/articles/amazon-ai-nvidia/dcard-02.webp Dcard 原圖：亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia）（圖 2）亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia） https://drugnews.com.tw/assets/articles/amazon-ai-nvidia/dcard-03.png Dcard 原圖：亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia）（圖 3）亞馬遜（Amazon）參戰 AI 製藥，挑戰輝達（Nvidia） https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-01.webp Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 1）一篇文章講通現在的“禮來”併購邏輯 https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-02.webp Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 2）一篇文章講通現在的“禮來”併購邏輯 https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-03.png Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 3）一篇文章講通現在的“禮來”併購邏輯 https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-04.png Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 4）一篇文章講通現在的“禮來”併購邏輯 https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-01.webp Dcard 原圖：灰色產業上牌桌（圖 1）灰色產業上牌桌 https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-02.webp Dcard 原圖：灰色產業上牌桌（圖 2）灰色產業上牌桌 https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-03.png Dcard 原圖：灰色產業上牌桌（圖 3）灰色產業上牌桌 https://drugnews.com.tw/articles/2026-04-27-car-t.html https://drugnews.com.tw/assets/articles/car-t/dcard-01.webp Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 1）再見自體CAR-T，台灣的泡沫也該破了 https://drugnews.com.tw/assets/articles/car-t/dcard-02.webp Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 2）再見自體CAR-T，台灣的泡沫也該破了 https://drugnews.com.tw/assets/articles/car-t/dcard-03.png Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 3）再見自體CAR-T，台灣的泡沫也該破了 https://drugnews.com.tw/assets/articles/car-t/dcard-04.png Dcard 原圖：再見自體CAR-T，台灣的泡沫也該破了（圖 4）再見自體CAR-T，台灣的泡沫也該破了 https://drugnews.com.tw/articles/2026-04-26-dcard-261370593.html https://drugnews.com.tw/assets/articles/dcard-261370593/dcard-01.webp Dcard 原圖：醫療巨頭分拆潮？（圖 1）醫療巨頭分拆潮？ https://drugnews.com.tw/assets/articles/dcard-261370593/dcard-02.png Dcard 原圖：醫療巨頭分拆潮？（圖 2）醫療巨頭分拆潮？ https://drugnews.com.tw/assets/articles/dcard-261370593/dcard-03.png Dcard 原圖：醫療巨頭分拆潮？（圖 3）醫療巨頭分拆潮？ https://drugnews.com.tw/articles/2026-04-25-biotech-5.html https://drugnews.com.tw/assets/articles/biotech-5/dcard-01.webp Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 1）平台型 Biotech 的授權收入是同業的 5 倍？ https://drugnews.com.tw/assets/articles/biotech-5/dcard-02.webp Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 2）平台型 Biotech 的授權收入是同業的 5 倍？ https://drugnews.com.tw/assets/articles/biotech-5/dcard-03.webp Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 3）平台型 Biotech 的授權收入是同業的 5 倍？ https://drugnews.com.tw/assets/articles/biotech-5/dcard-04.png Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 4）平台型 Biotech 的授權收入是同業的 5 倍？ https://drugnews.com.tw/assets/articles/biotech-5/dcard-05.png Dcard 原圖：平台型 Biotech 的授權收入是同業的 5 倍？（圖 5）平台型 Biotech 的授權收入是同業的 5 倍？ https://drugnews.com.tw/articles/2026-04-24-dcard-261359193.html https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-01.webp Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 1）投資人請注意，給藥方式是藍海！ https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-02.webp Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 2）投資人請注意，給藥方式是藍海！ https://drugnews.com.tw/assets/articles/dcard-261359193/dcard-03.png Dcard 原圖：投資人請注意，給藥方式是藍海！（圖 3）投資人請注意，給藥方式是藍海！ https://drugnews.com.tw/articles/2026-04-23-dcard-261352566.html https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-01.webp Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 1）慢性阻塞性肺病患者又有新藥可以用了？ https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-02.webp Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 2）慢性阻塞性肺病患者又有新藥可以用了？ https://drugnews.com.tw/assets/articles/dcard-261352566/dcard-03.png Dcard 原圖：慢性阻塞性肺病患者又有新藥可以用了？（圖 3）慢性阻塞性肺病患者又有新藥可以用了？ https://drugnews.com.tw/articles/2026-04-22-ai.html https://drugnews.com.tw/assets/articles/ai/dcard-01.webp Dcard 原圖：AI三巨頭在醫藥裡廝殺（圖 1） AI三巨頭在醫藥裡廝殺 https://drugnews.com.tw/assets/articles/ai/dcard-02.webp Dcard 原圖：AI三巨頭在醫藥裡廝殺（圖 2） AI三巨頭在醫藥裡廝殺 https://drugnews.com.tw/assets/articles/ai/dcard-03.webp Dcard 原圖：AI三巨頭在醫藥裡廝殺（圖 3） AI三巨頭在醫藥裡廝殺 https://drugnews.com.tw/assets/articles/ai/dcard-04.webp Dcard 原圖：AI三巨頭在醫藥裡廝殺（圖 4） AI三巨頭在醫藥裡廝殺 https://drugnews.com.tw/assets/articles/ai/dcard-05.png Dcard 原圖：AI三巨頭在醫藥裡廝殺（圖 5） AI三巨頭在醫藥裡廝殺 https://drugnews.com.tw/articles/2026-04-21-dcard-261339270.html https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-01.webp Dcard 原圖：禮來口服藥引爆市場？（圖 1）禮來口服藥引爆市場？ https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-02.webp Dcard 原圖：禮來口服藥引爆市場？（圖 2）禮來口服藥引爆市場？ https://drugnews.com.tw/assets/articles/dcard-261339270/dcard-03.png Dcard 原圖：禮來口服藥引爆市場？（圖 3）禮來口服藥引爆市場？ https://drugnews.com.tw/articles/2026-04-20-dcard-261332702.html https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-01.webp Dcard 原圖：歷史性一刻，世紀大藥來了（圖 1）歷史性一刻，世紀大藥來了 https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-02.webp Dcard 原圖：歷史性一刻，世紀大藥來了（圖 2）歷史性一刻，世紀大藥來了 https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-03.webp Dcard 原圖：歷史性一刻，世紀大藥來了（圖 3）歷史性一刻，世紀大藥來了 https://drugnews.com.tw/assets/articles/dcard-261332702/dcard-04.webp Dcard 原圖：歷史性一刻，世紀大藥來了（圖 4）歷史性一刻，世紀大藥來了 https://drugnews.com.tw/articles/2026-04-19-neuralink-10.html https://drugnews.com.tw/assets/articles/neuralink-10/dcard-01.webp Dcard 原圖：馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！（圖 1）馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！ https://drugnews.com.tw/assets/articles/neuralink-10/dcard-02.webp Dcard 原圖：馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！（圖 2）馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！ https://drugnews.com.tw/assets/articles/neuralink-10/dcard-03.png Dcard 原圖：馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！（圖 3）馬斯克的下一個兆元美金賽道 Neuralink，你必須知道的腦機介面 10 家！ https://drugnews.com.tw/articles/2026-04-18-biotech-ai.html https://drugnews.com.tw/assets/articles/biotech-ai/dcard-01.webp Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 1）台灣這家Biotech將吃下AI基礎建設的所有紅利？ https://drugnews.com.tw/assets/articles/biotech-ai/dcard-02.png Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 2）台灣這家Biotech將吃下AI基礎建設的所有紅利？ https://drugnews.com.tw/assets/articles/biotech-ai/dcard-03.png Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 3）台灣這家Biotech將吃下AI基礎建設的所有紅利？ https://drugnews.com.tw/assets/articles/biotech-ai/dcard-04.png Dcard 原圖：台灣這家Biotech將吃下AI基礎建設的所有紅利？（圖 4）台灣這家Biotech將吃下AI基礎建設的所有紅利？ https://drugnews.com.tw/articles/2026-04-17-dcard-261315054.html https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-01.webp Dcard 原圖：創新藥開發的「死亡之谷」（圖 1）創新藥開發的「死亡之谷」 https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-02.webp Dcard 原圖：創新藥開發的「死亡之谷」（圖 2）創新藥開發的「死亡之谷」 https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-03.webp Dcard 原圖：創新藥開發的「死亡之谷」（圖 3）創新藥開發的「死亡之谷」 https://drugnews.com.tw/assets/articles/dcard-261315054/dcard-04.png Dcard 原圖：創新藥開發的「死亡之谷」（圖 4）創新藥開發的「死亡之谷」 https://drugnews.com.tw/articles/2026-04-16-2026-q2.html https://drugnews.com.tw/assets/articles/2026-q2/dcard-01.webp Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 1）生技人必須知道的 2026 Q2 重磅藥物 https://drugnews.com.tw/assets/articles/2026-q2/dcard-02.webp Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 2）生技人必須知道的 2026 Q2 重磅藥物 https://drugnews.com.tw/assets/articles/2026-q2/dcard-03.png Dcard 原圖：生技人必須知道的 2026 Q2 重磅藥物（圖 3）生技人必須知道的 2026 Q2 重磅藥物 https://drugnews.com.tw/articles/2026-04-15-biotech.html https://drugnews.com.tw/assets/articles/biotech/dcard-01.webp Dcard 原圖：兩家明星 Biotech 的隕落（圖 1）兩家明星 Biotech 的隕落 https://drugnews.com.tw/assets/articles/biotech/dcard-02.webp Dcard 原圖：兩家明星 Biotech 的隕落（圖 2）兩家明星 Biotech 的隕落 https://drugnews.com.tw/assets/articles/biotech/dcard-03.png Dcard 原圖：兩家明星 Biotech 的隕落（圖 3）兩家明星 Biotech 的隕落 https://drugnews.com.tw/assets/articles/biotech/dcard-04.png Dcard 原圖：兩家明星 Biotech 的隕落（圖 4）兩家明星 Biotech 的隕落 https://drugnews.com.tw/articles/2026-04-14-dcard-261295358.html https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-01.webp Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 1）投資人請注意，自體免疫超大藥賽道 https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-02.webp Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 2）投資人請注意，自體免疫超大藥賽道 https://drugnews.com.tw/assets/articles/dcard-261295358/dcard-03.png Dcard 原圖：投資人請注意，自體免疫超大藥賽道（圖 3）投資人請注意，自體免疫超大藥賽道 https://drugnews.com.tw/articles/2026-04-13-78.html https://drugnews.com.tw/assets/articles/78/dcard-01.webp Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 1）減肥藥之王 78億美元，買下一個「清醒時代」？ https://drugnews.com.tw/assets/articles/78/dcard-02.webp Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 2）減肥藥之王 78億美元，買下一個「清醒時代」？ https://drugnews.com.tw/assets/articles/78/dcard-03.png Dcard 原圖：減肥藥之王 78億美元，買下一個「清醒時代」？（圖 3）減肥藥之王 78億美元，買下一個「清醒時代」？ https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-01.webp Dcard 原圖：特發性肺纖維化迎來爆發（圖 1）特發性肺纖維化迎來爆發 https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-02.webp Dcard 原圖：特發性肺纖維化迎來爆發（圖 2）特發性肺纖維化迎來爆發 https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-03.png Dcard 原圖：特發性肺纖維化迎來爆發（圖 3）特發性肺纖維化迎來爆發 https://drugnews.com.tw/articles/2026-04-11-dcard-261276232.html https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-01.webp Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 1）這家公司臨床試驗失敗，反而被更加看好？ https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-02.webp Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 2）這家公司臨床試驗失敗，反而被更加看好？ https://drugnews.com.tw/assets/articles/dcard-261276232/dcard-03.png Dcard 原圖：這家公司臨床試驗失敗，反而被更加看好？（圖 3）這家公司臨床試驗失敗，反而被更加看好？ https://drugnews.com.tw/articles/2026-04-10-dcard-261269760.html https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-01.webp Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 1）何時果斷放棄新藥臨床試驗開發？ https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-02.webp Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 2）何時果斷放棄新藥臨床試驗開發？ https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-03.png Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 3）何時果斷放棄新藥臨床試驗開發？ https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-04.png Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 4）何時果斷放棄新藥臨床試驗開發？ https://drugnews.com.tw/assets/articles/dcard-261269760/dcard-05.png Dcard 原圖：何時果斷放棄新藥臨床試驗開發？（圖 5）何時果斷放棄新藥臨床試驗開發？ https://drugnews.com.tw/articles/2026-04-09-dcard-261263509.html https://drugnews.com.tw/assets/articles/dcard-261263509/dcard-01.webp Dcard 原圖：這一批罕見病患者終於等來新藥！（圖 1）這一批罕見病患者終於等來新藥！ https://drugnews.com.tw/assets/articles/dcard-261263509/dcard-02.png Dcard 原圖：這一批罕見病患者終於等來新藥！（圖 2）這一批罕見病患者終於等來新藥！ https://drugnews.com.tw/articles/2026-04-08-abivax-14.html https://drugnews.com.tw/assets/articles/abivax-14/dcard-01.webp Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 1）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/assets/articles/abivax-14/dcard-02.webp Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 2）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/assets/articles/abivax-14/dcard-03.webp Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 3）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/assets/articles/abivax-14/dcard-04.png Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 4）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/assets/articles/abivax-14/dcard-05.png Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 5）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/assets/articles/abivax-14/dcard-06.png Dcard 原圖：歐洲生技公司Abivax 一年暴漲14倍的神話（圖 6）歐洲生技公司Abivax 一年暴漲14倍的神話 https://drugnews.com.tw/articles/2026-04-07-cdc.html https://drugnews.com.tw/assets/articles/cdc/dcard-01.webp Dcard 原圖：當美國 CDC 還在找主任...（圖 1）當美國 CDC 還在找主任... https://drugnews.com.tw/assets/articles/cdc/dcard-02.webp Dcard 原圖：當美國 CDC 還在找主任...（圖 2）當美國 CDC 還在找主任... https://drugnews.com.tw/assets/articles/cdc/dcard-03.png Dcard 原圖：當美國 CDC 還在找主任...（圖 3）當美國 CDC 還在找主任... https://drugnews.com.tw/articles/2026-04-06-420.html https://drugnews.com.tw/assets/articles/420/dcard-01.webp Dcard 原圖：骨折價瘦瘦針來了，每月420塊台幣（圖 1）骨折價瘦瘦針來了，每月420塊台幣 https://drugnews.com.tw/assets/articles/420/dcard-02.webp Dcard 原圖：骨折價瘦瘦針來了，每月420塊台幣（圖 2）骨折價瘦瘦針來了，每月420塊台幣 https://drugnews.com.tw/assets/articles/420/dcard-03.png Dcard 原圖：骨折價瘦瘦針來了，每月420塊台幣（圖 3）骨折價瘦瘦針來了，每月420塊台幣 https://drugnews.com.tw/articles/2026-04-05-dcard-261238352.html https://drugnews.com.tw/assets/articles/dcard-261238352/dcard-01.webp Dcard 原圖：我們離真正的抗老藥，究竟還有多遠？（圖 1）我們離真正的抗老藥，究竟還有多遠？ https://drugnews.com.tw/assets/articles/dcard-261238352/dcard-02.webp Dcard 原圖：我們離真正的抗老藥，究竟還有多遠？（圖 2）我們離真正的抗老藥，究竟還有多遠？ https://drugnews.com.tw/assets/articles/dcard-261238352/dcard-03.png Dcard 原圖：我們離真正的抗老藥，究竟還有多遠？（圖 3）我們離真正的抗老藥，究竟還有多遠？ https://drugnews.com.tw/articles/2026-04-04-dcard-261232633.html https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-01.webp Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 1）瘦瘦針翻車？導致胰臟炎？ https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-02.webp Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 2）瘦瘦針翻車？導致胰臟炎？ https://drugnews.com.tw/assets/articles/dcard-261232633/dcard-03.png Dcard 原圖：瘦瘦針翻車？導致胰臟炎？（圖 3）瘦瘦針翻車？導致胰臟炎？ https://drugnews.com.tw/articles/2026-04-03-dcard-261227197.html https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-01.webp Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 1）瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？ https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-02.webp Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 2）瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？ https://drugnews.com.tw/assets/articles/dcard-261227197/dcard-03.png Dcard 原圖：瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？（圖 3）瘦瘦針、猛健樂之後，減肥藥研發正在發生什麼事？ https://drugnews.com.tw/articles/2026-04-02-dcard-261221419.html https://drugnews.com.tw/assets/articles/dcard-261221419/dcard-01.webp Dcard 原圖：默沙東還能再造一個腫瘤帝國嗎？（圖 1）默沙東還能再造一個腫瘤帝國嗎？ https://drugnews.com.tw/assets/articles/dcard-261221419/dcard-02.webp Dcard 原圖：默沙東還能再造一個腫瘤帝國嗎？（圖 2）默沙東還能再造一個腫瘤帝國嗎？ https://drugnews.com.tw/assets/articles/dcard-261221419/dcard-03.png Dcard 原圖：默沙東還能再造一個腫瘤帝國嗎？（圖 3）默沙東還能再造一個腫瘤帝國嗎？ https://drugnews.com.tw/articles/2026-04-01-dcard-261215001.html https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-01.webp Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 1）信達的全球化列車，台灣的圓祥搭上了？ https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-02.webp Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 2）信達的全球化列車，台灣的圓祥搭上了？ https://drugnews.com.tw/assets/articles/dcard-261215001/dcard-03.png Dcard 原圖：信達的全球化列車，台灣的圓祥搭上了？（圖 3）信達的全球化列車，台灣的圓祥搭上了？